Pharsight

1. Drug name - ABILIFY MAINTENA KIT

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11154553	OTSUKA PHARM CO LTD	Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function	Sep, 2033 (10 years from now)
US10980803	OTSUKA PHARM CO LTD	Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function	Sep, 2033 (10 years from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Treatment: Treatment of schizophrenia, with efficacy in treating acute episodes of schizophrenia; treatment of schizophrenia; maintenance monotherapy treatment of bipolar i disorder; Treatment of schizophrenia; treatment of schizophrenia, with efficacy in treating acute episodes of schizophrenia

Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

Strength	Dosage	Availability
300MG/VIAL	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
300MG	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
400MG/VIAL	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
400MG	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription

2. Drug name - ABILIFY MYCITE KIT

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9268909	OTSUKA	Apparatus, system, and method to adaptively optimize power dissipation and broadcast power in a power source for a communication device	Oct, 2033 (11 years from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Treatment: Method of using a logic circuit to stabilize battery voltage supplied to a sensor embedded with a tablet and that communicates information via a signal through the body of a patient to a receiver

Dosage: TABLET;ORAL

Strength	Dosage	Availability
2MG	TABLET;ORAL	Prescription
5MG	TABLET;ORAL	Prescription
10MG	TABLET;ORAL	Prescription
15MG	TABLET;ORAL	Prescription
20MG	TABLET;ORAL	Prescription
30MG	TABLET;ORAL	Prescription

3. Drug name - ACZONE

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9161926	ALMIRALL	Topical dapsone and dapsone/adaplene compositions and methods for use thereof	Nov, 2033 (11 years from now)
US9517219	ALMIRALL	Topical dapsone and dapsone/adapalene compositions and methods for use thereof	Nov, 2033 (11 years from now)

Drugs and Companies using DAPSONE ingredient

Treatment: Topical treatment of acne vulgaris

Dosage: GEL;TOPICAL

Strength	Dosage	Availability
7.5%	GEL;TOPICAL	Prescription

4. Drug name - AKLIEF

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9498465	GALDERMA LABS LP	Topical compositions in the form of a gel containing a particular solubilized retinoid	May, 2033 (10 years from now)
US9084778	GALDERMA LABS LP	Topical compositions containing a retinoid of the oil-in-water emulsion type	May, 2033 (10 years from now)

Drugs and Companies using TRIFAROTENE ingredient

Treatment: Topical treatment of acne vulgaris; Treatment of acne vulgaris

Dosage: CREAM;TOPICAL

Strength	Dosage	Availability
0.005%	CREAM;TOPICAL	Prescription

5. Drug name - ALKINDI SPRINKLE

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9675559	ETON	Treatment of adrenal insufficiency	Jan, 2033 (10 years from now)

Drugs and Companies using HYDROCORTISONE ingredient

Treatment: Treatment of adrenal insufficiency

Dosage: GRANULE;ORAL

Strength	Dosage	Availability
0.5MG	GRANULE;ORAL	Prescription
1MG	GRANULE;ORAL	Prescription
2MG	GRANULE;ORAL	Prescription
5MG	GRANULE;ORAL	Prescription

6. Drug name - ANTARA (MICRONIZED)

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9314447	LUPIN	Reduced dose pharmaceutical compositions of fenofibrate	May, 2033 (10 years from now)

Drugs and Companies using FENOFIBRATE ingredient

Treatment: Treating primary hypercholesterolemia and mixed dyslipidemia; treating severe hypertriglyceridemia

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
30MG	CAPSULE;ORAL	Prescription
43MG	CAPSULE;ORAL	Prescription
87MG	CAPSULE;ORAL	Discontinued
90MG	CAPSULE;ORAL	Prescription
130MG	CAPSULE;ORAL	Prescription

7. Drug name - ARISTADA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9193685	ALKERMES INC	Pharmaceutical compositions having improved storage stability	Oct, 2033 (11 years from now)
US11097006	ALKERMES INC	Pharmaceutical compositions having improved storage stability	Oct, 2033 (11 years from now)

Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient

Treatment: Treatment of schizophrenia

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

Strength	Dosage	Availability
441MG/1.6ML (275.63MG/ML)	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
662MG/2.4ML (275.83MG/ML)	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
882MG/3.2ML (275.63MG/ML)	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
1064MG/3.9ML (272.82MG/ML)	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription

8. Drug name - ARYMO ER

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9549899	ZYLA	Abuse deterrent pharmaceutical compositions for controlled release	Jul, 2033 (10 years from now)
US9044402	ZYLA	Abuse-deterrent pharmaceutical compositions for controlled release	Jul, 2033 (10 years from now)

Drugs and Companies using MORPHINE SULFATE ingredient

Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
15MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued
30MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued
60MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued

9. Drug name - AUSTEDO

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9550780	TEVA BRANDED PHARM	Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2	Sep, 2033 (10 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9296739	TEVA BRANDED PHARM	Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2	Sep, 2033 (10 years from now)
US9233959	TEVA BRANDED PHARM	Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2	Sep, 2033 (10 years from now)
US9814708	TEVA BRANDED PHARM	Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2	Sep, 2033 (10 years from now)

Drugs and Companies using DEUTETRABENAZINE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
6MG	TABLET;ORAL	Prescription
9MG	TABLET;ORAL	Prescription
12MG	TABLET;ORAL	Prescription

10. Drug name - BAXDELA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9493582	MELINTA	Alkylated cyclodextrin compositions and processes for preparing and using the same	Feb, 2033 (10 years from now)

Drugs and Companies using DELAFLOXACIN MEGLUMINE ingredient

Treatment: NA

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
EQ 300MG BASE/VIAL	POWDER;INTRAVENOUS	Prescription

11. Drug name - BELSOMRA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10098892	MERCK SHARP DOHME	Solid dosage formulations of an orexin receptor antagonist	May, 2033 (10 years from now)

Drugs and Companies using SUVOREXANT ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
5MG	TABLET;ORAL	Prescription
10MG	TABLET;ORAL	Prescription
15MG	TABLET;ORAL	Prescription
20MG	TABLET;ORAL	Prescription

12. Drug name - BENDEKA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9000021	EAGLE PHARMS	Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration	Mar, 2033 (10 years from now)
US9597398	EAGLE PHARMS	Formulations of bendamustine	Mar, 2033 (10 years from now)
US9144568	EAGLE PHARMS	Formulations of bendamustine	Mar, 2033 (10 years from now)
US10052385	EAGLE PHARMS	Formulations of bendamustine	Mar, 2033 (10 years from now)
US9597399	EAGLE PHARMS	Formulations of bendamustine	Mar, 2033 (10 years from now)
US9034908	EAGLE PHARMS	Formulations of bendamustine	Mar, 2033 (10 years from now)
US9597397	EAGLE PHARMS	Formulations of bendamustine	Mar, 2033 (10 years from now)
US9572887	EAGLE PHARMS	Formulations of bendamustine	Mar, 2033 (10 years from now)
US9579384	EAGLE PHARMS	Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration	Mar, 2033 (10 years from now)

Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient

Treatment: For use in the treatment of patients with chronic lymphocytic leukemia and/or non-hodgkins lymphoma; For the treatment of patients with chronic lymphocytic leukemia; For the treatment of patients with indolent b-cell non-hodgkin lymphoma; for the treatment of patients with chronic lymphocytic leukemia; For the treatment of patients with chronic lymphocytic leukemia; for the treatment of patients with indolent b-cell non-hodgkin lymphoma

Dosage: SOLUTION;IV (INFUSION)

Strength	Dosage	Availability
100MG/4ML (25MG/ML)	SOLUTION;IV (INFUSION)	Prescription

13. Drug name - BIKTARVY

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9732092	GILEAD SCIENCES INC	Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]OXAZEPINES and methods for treating viral infections	Dec, 2033 (11 years from now)
US9216996	GILEAD SCIENCES INC	Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepines and methods for treating viral infections	Dec, 2033 (11 years from now)
CN104995198A	GILEAD SCIENCES INC	Polycyclic - Carbamoyl-Pyridone Compounds And Pharmaceutical Use	Dec, 2033 (11 years from now)
CN107674086B	GILEAD SCIENCES INC	Polycyclic-Carbamoyl Pyridone Compounds And Pharmaceutical Use Thereof	Dec, 2033 (11 years from now)
CN104995198B	GILEAD SCIENCES INC	Polycyclic Carbamoyl Pyridone Compounds And Pharmaceutical Use Thereof	Dec, 2033 (11 years from now)
CN107674086A	GILEAD SCIENCES INC	Polycyclic Carbamoyl Pyridone Compounds And Pharmaceutical Use Thereof	Dec, 2033 (11 years from now)
IN201505535P1	GILEAD SCIENCES INC	Polycyclic Carbamoylpyridone Compounds And Their Pharmaceutical Use	Dec, 2033 (11 years from now)
IN371130B	GILEAD SCIENCES INC	Polycyclic Carbamoylpyridone Compounds And Their Pharmaceutical Use	Dec, 2033 (11 years from now)
IN201918019286A	GILEAD SCIENCES INC	Polycyclic-Carbamoylpyridone Compounds And Their Pharmaceutical Use	Dec, 2033 (11 years from now)
IN352932B	GILEAD SCIENCES INC	Polycyclic Carbamoylpyridone Compounds And Their Pharmaceutical Use	Dec, 2033 (11 years from now)
EP3067358A1	GILEAD SCIENCES INC	Polycyclic-Carbamoylpyridone Compounds And Their Pharmaceutical Use	Dec, 2033 (11 years from now)
EP3608325A1	GILEAD SCIENCES INC	Polycyclic-Carbamoylpyridone Compounds And Their Pharmaceutical Use	Dec, 2033 (11 years from now)
EP3067358B1	GILEAD SCIENCES INC	Polycyclic-Carbamoylpyridone Compounds And Their Pharmaceutical Use	Dec, 2033 (11 years from now)
EP3608325B1	GILEAD SCIENCES INC	Polycyclic-Carbamoylpyridone Compounds And Their Pharmaceutical Use	Dec, 2033 (11 years from now)
EP2822954A1	GILEAD SCIENCES INC	Polycyclic-Carbamoylpyridone Compounds And Their Pharmaceutical Use	Dec, 2033 (11 years from now)
EP2822954B1	GILEAD SCIENCES INC	Polycyclic-Carbamoylpyridone Compounds And Their Pharmaceutical Use	Dec, 2033 (11 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9296769 (Pediatric)	GILEAD SCIENCES INC	Tenofovir alafenamide hemifumarate	Feb, 2033 (10 years from now)
US8754065 (Pediatric)	GILEAD SCIENCES INC	Tenofovir alafenamide hemifumarate	Feb, 2033 (10 years from now)

Drugs and Companies using BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 30MG BASE;120MG;EQ 15MG BASE	TABLET;ORAL	Prescription
EQ 50MG BASE;200MG;EQ 25MG BASE	TABLET;ORAL	Prescription

14. Drug name - BONJESTA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9089489	DUCHESNAY	Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof	Feb, 2033 (10 years from now)
US9375404	DUCHESNAY	Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof	Feb, 2033 (10 years from now)
US9526703	DUCHESNAY	Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof	Feb, 2033 (10 years from now)
US9937132	DUCHESNAY	Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof	Feb, 2033 (10 years from now)

Drugs and Companies using DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE ingredient

Treatment: Treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
20MG;20MG	TABLET, EXTENDED RELEASE;ORAL	Prescription

15. Drug name - BRAFTOVI

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9474754	ARRAY BIOPHARMA INC	Pharmaceutical combinations comprising a B-RAF inhibitor, and EGFR inhibitor and optionally a PI3K-α inhibitor	Aug, 2033 (10 years from now)

Drugs and Companies using ENCORAFENIB ingredient

Treatment: Braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, as detected by an fda-approved test, after prior therapy

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
50MG	CAPSULE;ORAL	Discontinued
75MG	CAPSULE;ORAL	Prescription

16. Drug name - BYFAVO

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9561236	ACACIA	Dosing regimen for sedation with CNS 7056 (Remimazolam)	Apr, 2033 (10 years from now)

Drugs and Companies using REMIMAZOLAM BESYLATE ingredient

Treatment: Use of remimazolam for induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
EQ 20MG BASE/VIAL	POWDER;INTRAVENOUS	Prescription

17. Drug name - CABOMETYX

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9724342	EXELIXIS INC	C-met modulator pharmaceutical compositions	Jul, 2033 (10 years from now)

Drugs and Companies using CABOZANTINIB S-MALATE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 20MG BASE	TABLET;ORAL	Prescription
EQ 40MG BASE	TABLET;ORAL	Prescription
EQ 60MG BASE	TABLET;ORAL	Prescription

18. Drug name - CARNEXIV

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9493582	LUNDBECK PHARMS LLC	Alkylated cyclodextrin compositions and processes for preparing and using the same	Feb, 2033 (10 years from now)

Drugs and Companies using CARBAMAZEPINE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
200MG/20ML (10MG/ML)	SOLUTION;INTRAVENOUS	Discontinued

19. Drug name - CEQUA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10441630	SUN PHARM	Topical formulations and uses thereof	Aug, 2033 (10 years from now)
US8980839	SUN PHARM	Topical aqueous nanomicellar, ophthalmic solutions and uses thereof	Aug, 2033 (10 years from now)
US9937225	SUN PHARM	Topical formulations and uses thereof	Aug, 2033 (10 years from now)

Drugs and Companies using CYCLOSPORINE ingredient

Treatment: Increase tear production in patients with keratoconjunctivitis sicca (dry eye).

Dosage: SOLUTION;OPHTHALMIC

Strength	Dosage	Availability
0.09%	SOLUTION;OPHTHALMIC	Prescription

20. Drug name - CLOROTEKAL

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9504666	B BRAUN MEDICAL INC	Chloroprocaine-based pharmaceutical composition for repeated intrathecal administration	Dec, 2033 (11 years from now)

Drugs and Companies using CHLOROPROCAINE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: SOLUTION;INTRATHECAL

Strength	Dosage	Availability
50MG/5ML (10MG/ML)	SOLUTION;INTRATHECAL	Prescription

21. Drug name - COMPLERA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10857102	GILEAD SCIENCES INC	Therapeutic compositions comprising rilpivirine HCL and tenofovir disoproxil fumarate	Jan, 2033 (10 years from now)

Drugs and Companies using EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
200MG;EQ 25MG BASE;300MG	TABLET;ORAL	Prescription

22. Drug name - CONTRAVE

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10403170	NALPROPION	Methods of treating overweight and obesity	Jun, 2033 (10 years from now)
US11139056	NALPROPION	Methods of treating overweight and obesity	Jun, 2033 (10 years from now)
US9633575	NALPROPION	Methods of treating overweight and obesity	Jun, 2033 (10 years from now)

Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient

Treatment: For chronic weight management for treating overweight or obesity

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
90MG;8MG	TABLET, EXTENDED RELEASE;ORAL	Prescription

23. Drug name - CYTALUX

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9061057	ON TARGET LABS	Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors	Aug, 2033 (10 years from now)
US9333270	ON TARGET LABS	Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors	Aug, 2033 (10 years from now)
US9341629	ON TARGET LABS	Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors	Aug, 2033 (10 years from now)
US9789208	ON TARGET LABS	Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors	Aug, 2033 (10 years from now)
US10881747	ON TARGET LABS	Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors	Aug, 2033 (10 years from now)
US9254341	ON TARGET LABS	Methods of manufacture of pteroyl-amino acid-fluorescent dyes	Oct, 2033 (11 years from now)
CN105492905A	ON TARGET LABS	Fluorescent Imaging Of Inflammatory Disease	Aug, 2033 (10 years from now)
CN105492905B	ON TARGET LABS	Fluorescent Imaging Of Inflammatory Disease	Aug, 2033 (10 years from now)
CN105228628A	ON TARGET LABS	Synthesis And Composition Of Amino Acids Connection Base Used For Compound Conjugated With The Tumour-Targeted Imaging	Aug, 2033 (10 years from now)
CN105228628B	ON TARGET LABS	Synthesis And Composition Of Amino Acid Is Connected To The Compound Used For The Tumour-Targeted Imaging Of The Conjugated	Aug, 2033 (10 years from now)
IN364483B	ON TARGET LABS	Pteroyl Ligands With Near-Infared Fluoresence Probes And Method Of Uses Thereof	Aug, 2033 (10 years from now)
IN201508446P1	ON TARGET LABS	Synthesis And Composition Of Amino Acid Linking Groups Conjugated To Compounds Used For The Targeted Imaging Of Tumors	Aug, 2033 (10 years from now)
EP2968335A1	ON TARGET LABS	Synthesis And Composition Of Amino Acid Linking Groups Conjugated To Compounds Used For The Targeted Imaging Of Tumors	Aug, 2033 (10 years from now)
EP2968335A4	ON TARGET LABS	Synthesis And Composition Of Amino Acid Linking Groups Conjugated To Compounds Used For The Targeted Imaging Of Tumors	Aug, 2033 (10 years from now)
EP2968335B1	ON TARGET LABS	Synthesis And Composition Of Amino Acid Linking Groups Conjugated To Compounds Used For The Targeted Imaging Of Tumors	Aug, 2033 (10 years from now)
EP2968614A1	ON TARGET LABS	Methods Of Manufacture And Synthesis Of Amino Acid Linking Groups Conjugated To Compounds Used For Targeted Imaging Of Tumors	Oct, 2033 (11 years from now)
EP2968614A4	ON TARGET LABS	Methods Of Manufacture And Synthesis Of Amino Acid Linking Groups Conjugated To Compounds Used For Targeted Imaging Of Tumors	Oct, 2033 (11 years from now)
EP2968614B1	ON TARGET LABS	Methods Of Manufacture And Synthesis Of Amino Acid Linking Groups Conjugated To Compounds Used For Targeted Imaging Of Tumors	Oct, 2033 (11 years from now)
EP2972320A1	ON TARGET LABS	Methods Of Imaging Inflammatory Diseases By Ligands Conjugated To Fluorescent Compounds	Dec, 2033 (11 years from now)
EP2972320A4	ON TARGET LABS	Methods Of Imaging Inflammatory Diseases By Ligands Conjugated To Fluorescent Compounds	Dec, 2033 (11 years from now)
EP2972320B1	ON TARGET LABS	Methods Of Imaging Inflammatory Diseases By Ligands Conjugated To Fluorescent Compounds	Dec, 2033 (11 years from now)

Drugs and Companies using PAFOLACIANINE SODIUM ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
EQ 3.2MG BASE/1.6ML (EQ 2MG BASE/ML)	SOLUTION;INTRAVENOUS	Prescription

24. Drug name - DAPTOMYCIN

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10357535	HOSPIRA INC	Daptomycin formulations and uses thereof	Sep, 2033 (10 years from now)
US9655946	HOSPIRA INC	Daptomycin formulations and uses thereof	Sep, 2033 (10 years from now)

Drugs and Companies using DAPTOMYCIN ingredient

Treatment: Treatment of complicated skin and skin structure infections and s. aureus bloodstream infections (bacteremia) including those with right-sided infective endocarditis by reconstituting and administering the formulation as recited in claim 12; Treatment of complicated skin and skin structure infections and staphylococcus aureus bloodstream infections (bacteremia) including those with right-sided infective endocarditis by administering the formulation of daptomycin as recited in claim 18

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
350MG/VIAL	POWDER;INTRAVENOUS	Prescription
500MG/VIAL	POWDER;INTRAVENOUS	Prescription

25. Drug name - DESCOVY

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9296769 (Pediatric)	GILEAD SCIENCES INC	Tenofovir alafenamide hemifumarate	Feb, 2033 (10 years from now)
US8754065 (Pediatric)	GILEAD SCIENCES INC	Tenofovir alafenamide hemifumarate	Feb, 2033 (10 years from now)

Drugs and Companies using EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
120MG;EQ 15MG BASE	TABLET;ORAL	Prescription
200MG;EQ 25MG BASE	TABLET;ORAL	Prescription

26. Drug name - DOCETAXEL

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9763880	SHILPA	Non-aqueous taxane formulations and methods of using the same	Sep, 2033 (10 years from now)
US8940786	SHILPA	Non-aqueous taxane nanodispersion formulations and methods of using the same	Sep, 2033 (10 years from now)
US9308195	SHILPA	Non-aqueous taxane formulations and methods of using the same	Sep, 2033 (10 years from now)

Drugs and Companies using DOCETAXEL ingredient

Treatment: Treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy; treatment of patients with locally advanced squamous cell carcinoma of the head and neck in combination with cisplatin and fluorouracil; use in combination with doxorubicin and cyclophosphamide for adjuvant treatment of patients with operable node-positive breast cancer; treatment of patients with locally advanced metastatic breast cancer after failure of prior chemotherapy; use in combination with cisplatin for treatment of unresectable, locally advanced or metastatic non-small cell lung cancer without prior chemotherapy treatment; treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer in combination with prednisone; treatment of advanced gastric adenocarcinoma in combination with cisplatin and fluorouracil in patients that have not received prior chemotherapy; Method of administering an ethanol-free taxane liquid nanodispersion formulation to a subject combining the formulation with an aqueous medium to provide an ethanol-free taxane diluted solution

Dosage: INJECTABLE;INJECTION

Strength	Dosage	Availability
20MG/ML (20MG/ML)	INJECTABLE;INJECTION	Prescription
80MG/4ML (20MG/ML)	INJECTABLE;INJECTION	Prescription
160MG/8ML (20MG/ML)	INJECTABLE;INJECTION	Prescription

27. Drug name - EMPAVELI

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10125171	APELLIS PHARMS	Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof	Aug, 2033 (10 years from now)
US10035822	APELLIS PHARMS	Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods	Nov, 2033 (11 years from now)
US10875893	APELLIS PHARMS	Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods	Nov, 2033 (11 years from now)
CN105051057B	APELLIS PHARMS	Cell Reactivity, Release Or Targeting Of Compstatin Analogs And Related Compositions And Methods	Nov, 2033 (11 years from now)
CN105051057A	APELLIS PHARMS	Cell Reactive, Long-Acting Or Targeting Camp Statin Analogue And Related Composition And Method	Nov, 2033 (11 years from now)
IN363846B	APELLIS PHARMS	Cell-Reactive, Long-Acting, Or Targeted Compstatin Analogs And Related Compositions And Methods	Nov, 2033 (11 years from now)
IN201505048P1	APELLIS PHARMS	Cell- Reactive , Long -Acting ,Or Targeted Compstatin Analogs And Related Compositions And Methods	Nov, 2033 (11 years from now)
EP2920201A4	APELLIS PHARMS	Cell-Reactive, Long-Acting, Or Targeted Compstatin Analogs And Related Compositions And Methods	Nov, 2033 (11 years from now)
EP3660033B1	APELLIS PHARMS	Long-Acting Compstatin Analogs And Related Compositions And Methods	Nov, 2033 (11 years from now)
EP2920201B1	APELLIS PHARMS	Long-Acting Compstatin Analogs And Related Compositions And Methods	Nov, 2033 (11 years from now)
EP3660033B9	APELLIS PHARMS	Long-Acting Compstatin Analogs And Related Compositions And Methods	Nov, 2033 (11 years from now)
EP2920201A2	APELLIS PHARMS	Long-Acting Compstatin Analogs And Related Compositions And Methods	Nov, 2033 (11 years from now)
EP3660033A1	APELLIS PHARMS	Long-Acting Compstatin Analogs And Related Compositions And Methods	Nov, 2033 (11 years from now)

Drugs and Companies using PEGCETACOPLAN ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

Strength	Dosage	Availability
1080MG/20ML (54MG/ML)	SOLUTION;SUBCUTANEOUS	Prescription

28. Drug name - ENTRESTO

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11135192	NOVARTIS PHARMS CORP	Inhibitors for treating diseases characterized by atrial enlargement or remodeling	Aug, 2033 (10 years from now)
US9517226	NOVARTIS PHARMS CORP	Inhibitors for treating diseases characterized by atrial enlargement or remodeling	Aug, 2033 (10 years from now)
US9937143	NOVARTIS PHARMS CORP	Inhibitors for treating diseases characterized by atrial enlargement or remodeling	Aug, 2033 (10 years from now)

Drugs and Companies using SACUBITRIL; VALSARTAN ingredient

Treatment: Treatment of heart failure with preserved ejection fraction

Dosage: TABLET;ORAL

Strength	Dosage	Availability
24MG;26MG	TABLET;ORAL	Prescription
49MG;51MG	TABLET;ORAL	Prescription
97MG;103MG	TABLET;ORAL	Prescription

29. Drug name - EPANOVA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9050309	ASTRAZENECA	DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form	Jan, 2033 (10 years from now)
IN201406125P1	ASTRAZENECA	Dpa-Enriched Compositions Of Omega-3 Polyunsaturated Fatty Acids In Free Acid Form	Jan, 2033 (10 years from now)
IN344039B	ASTRAZENECA	Dpa Enriched Compositions Of Omega 3 Polyunsaturated Fatty Acids In Free Acid Form	Jan, 2033 (10 years from now)
EP2800563A4	ASTRAZENECA	Dpa-Enriched Compositions Of Omega-3 Polyunsaturated Fatty Acids In Free Acid Form	Jan, 2033 (10 years from now)
EP2800563B1	ASTRAZENECA	Dpa-Enriched Compositions Of Omega-3 Polyunsaturated Fatty Acids In Free Acid Form	Jan, 2033 (10 years from now)
EP2800563A1	ASTRAZENECA	Dpa-Enriched Compositions Of Omega-3 Polyunsaturated Fatty Acids In Free Acid Form	Jan, 2033 (10 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10117844	ASTRAZENECA	DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form	Jan, 2033 (10 years from now)
US9050308	ASTRAZENECA	DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form	Jan, 2033 (10 years from now)

Drugs and Companies using OMEGA-3-CARBOXYLIC ACIDS ingredient

Treatment: Treatment of severe hypertriglyceridemia (500 mg/dl) in adult patients as an adjunct to diet; Treatment of hypertriglyceridemia

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
1GM CONTAINS AT LEAST 850MG OF POLYUNSATURATED FATTY ACIDS	CAPSULE;ORAL	Discontinued

30. Drug name - EPCLUSA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8575135 (Pediatric)	GILEAD SCIENCES INC	Antiviral compounds	May, 2033 (10 years from now)
US8921341 (Pediatric)	GILEAD SCIENCES INC	Antiviral compounds	May, 2033 (10 years from now)
US8940718 (Pediatric)	GILEAD SCIENCES INC	Antiviral compounds	May, 2033 (10 years from now)

Drugs and Companies using SOFOSBUVIR; VELPATASVIR ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
200MG;50MG	TABLET;ORAL	Prescription
400MG;100MG	TABLET;ORAL	Prescription

31. Drug name - ERLEADA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9481663	JANSSEN BIOTECH	Crystalline forms of an androgen receptor modulator	Jun, 2033 (10 years from now)
EP3348553A1	JANSSEN BIOTECH	Crystalline Forms Of An Androgen Receptor Modulator	Jun, 2033 (10 years from now)
EP3348553B1	JANSSEN BIOTECH	Crystalline Forms Of An Androgen Receptor Modulator	Jun, 2033 (10 years from now)
EP2858985B1	JANSSEN BIOTECH	Crystalline Forms Of An Androgen Receptor Modulator	Jun, 2033 (10 years from now)
EP2858985A4	JANSSEN BIOTECH	Crystalline Forms Of An Androgen Receptor Modulator	Jun, 2033 (10 years from now)
EP2858985A1	JANSSEN BIOTECH	Crystalline Forms Of An Androgen Receptor Modulator	Jun, 2033 (10 years from now)
EP3533792B1	JANSSEN BIOTECH	Crystalline Forms Of An Androgen Receptor Modulator	Jun, 2033 (10 years from now)
EP3533792A1	JANSSEN BIOTECH	Crystalline Forms Of An Androgen Receptor Modulator	Jun, 2033 (10 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10849888	JANSSEN BIOTECH	Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer	Sep, 2033 (10 years from now)
US10052314	JANSSEN BIOTECH	Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer	Sep, 2033 (10 years from now)
US9884054	JANSSEN BIOTECH	Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer	Sep, 2033 (10 years from now)

Drugs and Companies using APALUTAMIDE ingredient

Treatment: Treatment in combination with orchiectomy of non-metastatic, castration-resistant prostate cancer (nmcrpc); Treatment in combination with a gnrh agonist of non-metastatic, castration-resistant prostate cancer (nm-crpc); treatment in combination with a gnrh agonist of high risk non-metastatic, castration-resistant prostate cancer (nm-crpc); Treatment of non-metastatic, castration-resistant prostate cancer (nm-crpc)

Dosage: TABLET;ORAL

Strength	Dosage	Availability
60MG	TABLET;ORAL	Prescription

32. Drug name - ESBRIET

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8778947	GENENTECH INC	Methods of administering pirfenidone therapy	Aug, 2033 (10 years from now)

Drugs and Companies using PIRFENIDONE ingredient

Treatment: Dose reduction of pirfenidone by about one half during concurrent administration of ciprofloxacin at a dose of 750 mg twice daily (1500 mg/day) to reduce drug interactions in treatment of a fibrotic, inflammatory, or autoimmune disorder; administration of pirfenidone and avoiding concurrent administration of ciprofloxacin at a dose of 750 mg to reduce drug interactions in treatment of a fibrotic, inflammatory, or autoimmune disorder

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
267MG	CAPSULE;ORAL	Prescription

33. Drug name - ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8829054	HQ SPCLT PHARMA	Ready-to-use co-solvents pharmaceutical composition in modified flexible plastic container	Mar, 2033 (10 years from now)
US8835505	HQ SPCLT PHARMA	Ready-to-use co-solvents pharmaceutical composition in modified flexible plastic container	Mar, 2033 (10 years from now)

Drugs and Companies using ESMOLOL HYDROCHLORIDE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
2GM/100ML (20MG/ML)	SOLUTION;INTRAVENOUS	Prescription
2.5GM/250ML (10MG/ML)	SOLUTION;INTRAVENOUS	Prescription

34. Drug name - EVOMELA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9493582	ACROTECH	Alkylated cyclodextrin compositions and processes for preparing and using the same	Feb, 2033 (10 years from now)

Drugs and Companies using MELPHALAN HYDROCHLORIDE ingredient

Treatment: NA

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
EQ 50MG BASE/VIAL	POWDER;INTRAVENOUS	Prescription

35. Drug name - EVRYSDI

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9586955	GENENTECH INC	Compounds for treating spinal muscular atrophy	Feb, 2033 (10 years from now)
CN104349777B	GENENTECH INC	For Compound For Treating Spinal Muscular Atrophy	Feb, 2033 (10 years from now)
CN104349777A	GENENTECH INC	Compounds For Treating Spinal Muscular Atrophy	Feb, 2033 (10 years from now)
EP2812004B1	GENENTECH INC	Compounds For Treating Spinal Muscular Atrophy	Feb, 2033 (10 years from now)
EP2812004A2	GENENTECH INC	Compounds For Treating Spinal Muscular Atrophy	Feb, 2033 (10 years from now)
EP2812004A4	GENENTECH INC	Compounds For Treating Spinal Muscular Atrophy	Feb, 2033 (10 years from now)
EP3406252A1	GENENTECH INC	Compounds For Treating Spinal Muscular Atrophy	Feb, 2033 (10 years from now)
EP3406252B1	GENENTECH INC	Compounds For Treating Spinal Muscular Atrophy	Feb, 2033 (10 years from now)

Drugs and Companies using RISDIPLAM ingredient

Treatment: NA

Dosage: FOR SOLUTION;ORAL

Strength	Dosage	Availability
0.75MG/ML	FOR SOLUTION;ORAL	Prescription

36. Drug name - EYSUVIS

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11219596	KALA PHARMS INC	Compositions and methods for ophthalmic and/or other applications	May, 2033 (10 years from now)
US10857096	KALA PHARMS INC	Compositions and methods for ophthalmic and/or other applications	May, 2033 (10 years from now)
US10945948	KALA PHARMS INC	Compositions and methods for ophthalmic and/or other applications	May, 2033 (10 years from now)
US10940108	KALA PHARMS INC	Compositions and methods for ophthalmic and/or other applications	May, 2033 (10 years from now)
US9532955	KALA PHARMS INC	Nanocrystals, compositions, and methods that aid particle transport in mucus	May, 2033 (10 years from now)
US9737491	KALA PHARMS INC	Nanocrystals, compositions, and methods that aid particle transport in mucus	May, 2033 (10 years from now)
US9056057	KALA PHARMS INC	Nanocrystals, compositions, and methods that aid particle transport in mucus	May, 2033 (10 years from now)
US9827191	KALA PHARMS INC	Compositions and methods for ophthalmic and/or other applications	May, 2033 (10 years from now)
US10058511	KALA PHARMS INC	Nanocrystals, compositions, and methods that aid particle transport in mucus	May, 2033 (10 years from now)
US10993908	KALA PHARMS INC	Compositions and methods for ophthalmic and/or other applications	May, 2033 (10 years from now)
US10688045	KALA PHARMS INC	Compositions and methods for ophthalmic and/or other applications	May, 2033 (10 years from now)
US9393213	KALA PHARMS INC	Nanocrystals, compositions, and methods that aid particle transport in mucus	May, 2033 (10 years from now)
US10646436	KALA PHARMS INC	Compositions and methods for ophthalmic and/or other applications	May, 2033 (10 years from now)

Drugs and Companies using LOTEPREDNOL ETABONATE ingredient

Treatment: A method for treating dry eye in a patient; A method for delivering a composition to a mucus membrane; A method for delivering a pharmaceutical agent across a mucosal barrier; Administration to the eye of a patient for treatment of dry eye condition

Dosage: SUSPENSION/DROPS;OPHTHALMIC

Strength	Dosage	Availability
0.25%	SUSPENSION/DROPS;OPHTHALMIC	Prescription

37. Drug name - FINTEPLA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9549909	ZOGENIX INC	Method for the treatment of dravet syndrome	May, 2033 (10 years from now)
US10478441	ZOGENIX INC	Method for the treatment of Dravet syndrome	May, 2033 (10 years from now)
US9610260	ZOGENIX INC	Method for the treatment of Dravet Syndrome	May, 2033 (10 years from now)
US9603814	ZOGENIX INC	Method for the treatment of Dravet syndrome	May, 2033 (10 years from now)
US10478442	ZOGENIX INC	Method for the treatment of Dravet Syndrome	May, 2033 (10 years from now)
US9603815	ZOGENIX INC	Method for the treatment of Dravet syndrome	May, 2033 (10 years from now)

Drugs and Companies using FENFLURAMINE HYDROCHLORIDE ingredient

Treatment: Use in combination with stiripentol, valproate, and clobazam for the treatment of seizures associated with dravet syndrome; Use in combination with stiripentol for the treatment of seizures associated with dravet syndrome

Dosage: SOLUTION;ORAL

Strength	Dosage	Availability
EQ 2.2MG BASE/ML	SOLUTION;ORAL	Prescription

38. Drug name - GENVOYA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8754065 (Pediatric)	GILEAD SCIENCES INC	Tenofovir alafenamide hemifumarate	Feb, 2033 (10 years from now)
US9296769 (Pediatric)	GILEAD SCIENCES INC	Tenofovir alafenamide hemifumarate	Feb, 2033 (10 years from now)
US10039718 (Pediatric)	GILEAD SCIENCES INC	Use of solid carrier particles to improve the processability of a pharmaceutical agent	Apr, 2033 (10 years from now)

Drugs and Companies using COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
150MG;150MG;200MG;EQ 10MG BASE	TABLET;ORAL	Prescription

39. Drug name - GIVLAARI

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10125364	ALNYLAM PHARMS INC	Compositions and methods for inhibiting expression of the ALAS1 gene	Mar, 2033 (10 years from now)
US9133461	ALNYLAM PHARMS INC	Compositions and methods for inhibiting expression of the ALAS1 gene	May, 2033 (10 years from now)
CN104540948A	ALNYLAM PHARMS INC	Composition And Method For Inhibiting The Expression Of The Alas1	Apr, 2033 (10 years from now)
CN109112131B	ALNYLAM PHARMS INC	Composition And Method For Inhibiting Alas1 Gene Expression	Apr, 2033 (10 years from now)
CN109112131A	ALNYLAM PHARMS INC	Composition And Method For Inhibiting The Expression Of The Alas1	Apr, 2033 (10 years from now)
CN104540948B	ALNYLAM PHARMS INC	Composition And Method For Inhibiting The Expression Of The Alas1	Apr, 2033 (10 years from now)
IN371332B	ALNYLAM PHARMS INC	Compositions And Methods For Inhibiting Expression Of The Alas1 Gene	Apr, 2033 (10 years from now)
IN201407093P4	ALNYLAM PHARMS INC	Compositions And Methods For Inhibiting Expression Of The Alas1 Gene	Apr, 2033 (10 years from now)
EP2836595A2	ALNYLAM PHARMS INC	Compositions And Methods For Inhibiting Expression Of The Alas1 Gene	Apr, 2033 (10 years from now)
EP2836595B1	ALNYLAM PHARMS INC	Compositions And Methods For Inhibiting Expression Of The Alas1 Gene	Apr, 2033 (10 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9631193	ALNYLAM PHARMS INC	Compositions and methods for inhibiting expression of the ALAS1 gene	Mar, 2033 (10 years from now)

Drugs and Companies using GIVOSIRAN SODIUM ingredient

Treatment: Treatment of acute hepatic porphyria

Dosage: SOLUTION;SUBCUTANEOUS

Strength	Dosage	Availability
EQ 189MG BASE/ML (EQ 189MG BASE/ML)	SOLUTION;SUBCUTANEOUS	Prescription

40. Drug name - HARVONI

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9393256 (Pediatric)	GILEAD SCIENCES INC	Methods for treating HCV	Mar, 2033 (10 years from now)

Drugs and Companies using LEDIPASVIR; SOFOSBUVIR ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
45MG;200MG	TABLET;ORAL	Prescription
90MG;400MG	TABLET;ORAL	Prescription

41. Drug name - HETLIOZ

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10945988	VANDA PHARMS INC	Treatment of circadian rhythm disorders	Jan, 2033 (10 years from now)
US9549913	VANDA PHARMS INC	Treatment of circadian rhythm disorders	Jan, 2033 (10 years from now)
US10449176	VANDA PHARMS INC	Treatment of circadian rhythm disorders	Jan, 2033 (10 years from now)
US9060995	VANDA PHARMS INC	Treatment of circadian rhythm disorders	Jan, 2033 (10 years from now)
US10149829	VANDA PHARMS INC	Treatment of circadian rhythm disorders	Jan, 2033 (10 years from now)
USRE46604	VANDA PHARMS INC	Treatment of circadian rhythm disorders	Jan, 2033 (10 years from now)
US9855241	VANDA PHARMS INC	Treatment of circadian rhythm disorders	Jan, 2033 (10 years from now)
US9539234	VANDA PHARMS INC	Treatment of circadian rhythm disorders	Jan, 2033 (10 years from now)
US10610510	VANDA PHARMS INC	Treatment of circadian rhythm disorders	Jan, 2033 (10 years from now)
US10980770	VANDA PHARMS INC	Treatment of circadian rhythm disorders	Jan, 2033 (10 years from now)

Drugs and Companies using TASIMELTEON ingredient

Treatment: Treatment of non-24 hour sleep-wake disorder by administering tasimelteon; Treatment of non-24-hour sleep-wake disorder; Treatment of non-24-hour sleep-wake disorder by avoiding the use of tasimelteon in combination with fluvoxamine; Treatment of non-24 hour sleep-wake disorder by avoiding the use of tasimelteon in combination with cyp1a2 strong inhibitors; treatment of nighttime sleep disturbances in smith-magenis syndrome non-24 hour sleep-wake disorder by avoiding the use of tasimelteon in combination with cyp1a2 strong inhibitors; Treatment of non-24 hour sleep-wake disorder by orally administering 20mg of tasimelteon once daily before bedtime; Treatment of non-24-hour sleep-wake disorder by avoiding the use of tasimelteon in combination with a strong cyp1a2 inhibitor; treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the avoiding the use of tasimelteon in combination with a strong cyp1a2 inhibitor; Treatment of nighttime sleep disturbances in smith-magenis syndrome by administering tasimelteon to patients with a smoking history; treatment of non-24 hour sleep-wake disorder by administering tasimelteon to patients with a smoking history; Treatment of nighttime sleep disturbances in smith-magenissyndrome by avoiding the administration of tasimelteon to smokers or to patients being treated with a cyp1a2 inhibitor; treatment of non-24 hour sleep-wake disorder by avoiding the administration of tasimelteon to smokers or to patients being treated with a cyp1a2 inhibitor

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
20MG	CAPSULE;ORAL	Prescription

42. Drug name - HETLIOZ LQ

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10980770	VANDA PHARMS INC	Treatment of circadian rhythm disorders	Jan, 2033 (10 years from now)
US10610510	VANDA PHARMS INC	Treatment of circadian rhythm disorders	Jan, 2033 (10 years from now)
US9539234	VANDA PHARMS INC	Treatment of circadian rhythm disorders	Jan, 2033 (10 years from now)
US10149829	VANDA PHARMS INC	Treatment of circadian rhythm disorders	Jan, 2033 (10 years from now)

Drugs and Companies using TASIMELTEON ingredient

Treatment: Treatment of nighttime sleep disturbances in smith-magenissyndrome by avoiding the administration of tasimelteon to smokers or to patients being treated with a cyp1a2 inhibitor; Treatment of nighttime sleep disturbances in smith-magenis syndrome by administering tasimelteon to patients with a smoking history; Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the avoiding the use of tasimelteon in combination with a strong cyp1a2 inhibitor; Treatment of nighttime sleep disturbances in smith-magenis syndrome non-24 hour sleep-wake disorder by avoiding the use of tasimelteon in combination with cyp1a2 strong inhibitors

Dosage: SUSPENSION;ORAL

Strength	Dosage	Availability
4MG/ML	SUSPENSION;ORAL	Prescription

43. Drug name - ICLUSIG

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9493470	TAKEDA PHARMS USA	Crystalline forms of 3-(imidazo[1,2-B] pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt	Dec, 2033 (11 years from now)
US11192897	TAKEDA PHARMS USA	Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt	Dec, 2033 (11 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11192895	TAKEDA PHARMS USA	Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt	Dec, 2033 (11 years from now)

Drugs and Companies using PONATINIB HYDROCHLORIDE ingredient

Treatment: A method for treating philadelphia chromosome positive acute lymphoblastic leukemia; a method for treating leukemia resulting from a mutation in the bcr-abl kinase domain; a method for treating chronic myeloid leukemia

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 10MG BASE	TABLET;ORAL	Prescription
EQ 15MG BASE	TABLET;ORAL	Prescription
EQ 30MG BASE	TABLET;ORAL	Prescription
EQ 45MG BASE	TABLET;ORAL	Prescription

44. Drug name - IDHIFA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9512107	CELGENE CORP	Therapeutically active compositions and their methods of use	Jan, 2033 (10 years from now)
CN108912066B	CELGENE CORP	Treating Active Compound And Using Method Thereof	Jan, 2033 (10 years from now)
CN104114543A	CELGENE CORP	Therapy Active Compound And Using Method Thereof	Jan, 2033 (10 years from now)
CN107417667A	CELGENE CORP	Therapy Active Compound And Using Method Thereof	Jan, 2033 (10 years from now)
CN107417667B	CELGENE CORP	Therapeutically Active Compounds And Methods Of Use Thereof	Jan, 2033 (10 years from now)
CN104114543B	CELGENE CORP	Therapeutically Active Compound And Its Using Method	Jan, 2033 (10 years from now)
CN108912066A	CELGENE CORP	A Therapeutically Active Compound And Using Method Thereof	Jan, 2033 (10 years from now)
EP3406608A1	CELGENE CORP	Therapeutically Active Compounds And Their Methods Of Use	Jan, 2033 (10 years from now)
EP3406608B8	CELGENE CORP	Therapeutically Active Compounds And Their Methods Of Use	Jan, 2033 (10 years from now)
EP2800743A1	CELGENE CORP	Therapeutically Active Compounds And Their Methods Of Use	Jan, 2033 (10 years from now)
EP2800743B1	CELGENE CORP	Therapeutically Active Compounds And Their Methods Of Use	Jan, 2033 (10 years from now)
EP3406608B1	CELGENE CORP	Therapeutically Active Compounds And Their Methods Of Use	Jan, 2033 (10 years from now)
EP2800743A4	CELGENE CORP	Therapeutically Active Compounds And Their Methods Of Use	Jan, 2033 (10 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10294215	CELGENE CORP	Therapeutically active compounds and their methods of use	Jan, 2033 (10 years from now)

Drugs and Companies using ENASIDENIB MESYLATE ingredient

Treatment: Treatment of relapsed or refractory acute myeloid leukemia (aml) with an isocitrate dehydrogenase-2 (idh2) mutation

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 50MG BASE	TABLET;ORAL	Prescription
EQ 100MG BASE	TABLET;ORAL	Prescription

45. Drug name - IMBRUVICA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10125140	PHARMACYCLICS INC	Crystalline forms of a bruton's tyrosine kinase inhibitor	Jun, 2033 (10 years from now)
US9725455	PHARMACYCLICS INC	Crystalline forms of a bruton's tyrosine kinase inhibitor	Jun, 2033 (10 years from now)
US10106548	PHARMACYCLICS INC	Crystalline forms of a Bruton's tyrosine kinase inhibitor	Jun, 2033 (10 years from now)
US9296753	PHARMACYCLICS INC	Crystalline forms of a Bruton's tyrosine kinase inhibitor	Oct, 2033 (11 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10294231	PHARMACYCLICS INC	Crystalline forms of a Bruton's tyrosine kinase inhibitor	Jun, 2033 (10 years from now)
US10961251	PHARMACYCLICS INC	Crystalline forms of a Bruton's tyrosine kinase inhibitor	Jun, 2033 (10 years from now)
US10752634	PHARMACYCLICS INC	Crystalline forms of a brutons tyrosine kinase inhibitor	Jun, 2033 (10 years from now)
US10294232	PHARMACYCLICS INC	Crystalline forms of a Bruton's tyrosine kinase inhibitor	Jun, 2033 (10 years from now)
US9713617	PHARMACYCLICS INC	Crystalline forms of a Bruton's tyrosine kinase inhibitor	Jun, 2033 (10 years from now)
US9540382	PHARMACYCLICS INC	Crystalline forms of a Bruton's tyrosine kinase inhibitor	Aug, 2033 (10 years from now)

Drugs and Companies using IBRUTINIB ingredient

Treatment: Treatment of marginal zone lymphoma; treatment of mantle cell lymphoma; treatment of chronic lymphocytic leukemia; treatment of small lymphocytic lymphoma; treatment of waldenstrom's macroglobulinemia; treatment of chronic lymphocytic leukemia

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
70MG	CAPSULE;ORAL	Prescription
140MG	CAPSULE;ORAL	Prescription

46. Drug name - IMVEXXY

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11123283	THERAPEUTICSMD INC	Soluble estradiol capsule for vaginal insertion	Jun, 2033 (10 years from now)
US10471072	THERAPEUTICSMD INC	Vaginal inserted estradiol pharmaceutical compositions and methods	Jun, 2033 (10 years from now)
US11065197	THERAPEUTICSMD INC	Soluble estradiol capsule for vaginal insertion	Jun, 2033 (10 years from now)
US10888516	THERAPEUTICSMD INC	Soluble estradiol capsule for vaginal insertion	Jun, 2033 (10 years from now)
US11116717	THERAPEUTICSMD INC	Soluble estradiol capsule for vaginal insertion	Jun, 2033 (10 years from now)
US10668082	THERAPEUTICSMD INC	Vaginal inserted estradiol pharmaceutical compositions and methods	Jun, 2033 (10 years from now)
US10568891	THERAPEUTICSMD INC	Vaginal inserted estradiol pharmaceutical compositions and methods	Jun, 2033 (10 years from now)
US10398708	THERAPEUTICSMD INC	Vaginal inserted estradiol pharmaceutical compositions and methods	Dec, 2033 (11 years from now)
US9180091	THERAPEUTICSMD INC	Soluble estradiol capsule for vaginal insertion	Dec, 2033 (11 years from now)
US10258630	THERAPEUTICSMD INC	Vaginal inserted estradiol pharmaceutical compositions and methods	Dec, 2033 (11 years from now)

Drugs and Companies using ESTRADIOL ingredient

Treatment: Treatment of a symptom of vulvar and vaginal atrophy; treatment of dyspareunia; Treatment of dyspareunia; treatment of a symptom of vulvar and vaginal atrophy; Treatment of a symptom of vulvar and vaginal atrophy; treatment of moderate to severe dyspareunia

Dosage: INSERT;VAGINAL

Strength	Dosage	Availability
0.004MG	INSERT;VAGINAL	Prescription
0.01MG	INSERT;VAGINAL	Prescription

47. Drug name - INFUGEM

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9241948	SUN PHARM	Ready to be infused gemcetabine solution	Jul, 2033 (10 years from now)

Drugs and Companies using GEMCITABINE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
EQ 1200MG BASE/120ML (EQ 10MG BASE/ML)	SOLUTION;INTRAVENOUS	Prescription
EQ 1300MG BASE/130ML (EQ 10MG BASE/ML)	SOLUTION;INTRAVENOUS	Prescription
EQ 1400MG BASE/140ML (EQ 10MG BASE/ML)	SOLUTION;INTRAVENOUS	Prescription
EQ 1500MG BASE/150ML (EQ 10MG BASE/ML)	SOLUTION;INTRAVENOUS	Prescription
EQ 1600MG BASE/160ML (EQ 10MG BASE/ML)	SOLUTION;INTRAVENOUS	Prescription
EQ 1700MG BASE/170ML (EQ 10MG BASE/ML)	SOLUTION;INTRAVENOUS	Prescription
EQ 1800MG BASE/180ML (EQ 10MG BASE/ML)	SOLUTION;INTRAVENOUS	Prescription
EQ 1900MG BASE/190ML (EQ 10MG BASE/ML)	SOLUTION;INTRAVENOUS	Prescription
EQ 2000MG BASE/200ML (EQ 10MG BASE/ML)	SOLUTION;INTRAVENOUS	Prescription
EQ 2200MG BASE/220ML (EQ 10MG BASE/ML)	SOLUTION;INTRAVENOUS	Prescription

48. Drug name - INVELTYS

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9393213	KALA PHARMS INC	Nanocrystals, compositions, and methods that aid particle transport in mucus	May, 2033 (10 years from now)
US10646437	KALA PHARMS INC	Compositions and methods for ophthalmic and/or other applications	May, 2033 (10 years from now)
US10688045	KALA PHARMS INC	Compositions and methods for ophthalmic and/or other applications	May, 2033 (10 years from now)
US9056057	KALA PHARMS INC	Nanocrystals, compositions, and methods that aid particle transport in mucus	May, 2033 (10 years from now)
US9532955	KALA PHARMS INC	Nanocrystals, compositions, and methods that aid particle transport in mucus	May, 2033 (10 years from now)
US10058511	KALA PHARMS INC	Nanocrystals, compositions, and methods that aid particle transport in mucus	May, 2033 (10 years from now)
US11219597	KALA PHARMS INC	Compositions and methods for ophthalmic and/or other applications	May, 2033 (10 years from now)
US10864219	KALA PHARMS INC	Compositions and methods for ophthalmic and/or other applications	May, 2033 (10 years from now)
US9827191	KALA PHARMS INC	Compositions and methods for ophthalmic and/or other applications	May, 2033 (10 years from now)
US9737491	KALA PHARMS INC	Nanocrystals, compositions, and methods that aid particle transport in mucus	May, 2033 (10 years from now)

Drugs and Companies using LOTEPREDNOL ETABONATE ingredient

Treatment: A method for delivering a composition to a mucus membrane; A method for delivering a pharmaceutical agent across a mucosal barrier; A method of reducing post-surgical pain following ocular surgery; a method of treating postoperative inflammation following ocular surgery; A method for treating ocular inflammation; A method for treating inflammation and/or other disorders in an eye of a patient

Dosage: SUSPENSION/DROPS;OPHTHALMIC

Strength	Dosage	Availability
1%	SUSPENSION/DROPS;OPHTHALMIC	Prescription

49. Drug name - IONSYS

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9095706	THE MEDICINES CO	Self-test for analgesic product	Feb, 2033 (10 years from now)

Drugs and Companies using FENTANYL HYDROCHLORIDE ingredient

Treatment: NA

Dosage: SYSTEM;IONTOPHORESIS, TRANSDERMAL

Strength	Dosage	Availability
EQ 40MCG BASE/ACTIVATION	SYSTEM;IONTOPHORESIS, TRANSDERMAL	Discontinued

50. Drug name - JENTADUETO XR

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9555001	BOEHRINGER INGELHEIM	Pharmaceutical composition and uses thereof	Mar, 2033 (10 years from now)

Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

Treatment: Method of treating type 2 diabetes in patients with insufficient glycemic control despite therapy with one or more conventional antihyperglycemic agents by administering linagliptin in combination with metformin; method of treating type 2 diabetes in patients who have not been previously treated with an antihyperglycemic agent by administering linagliptin in combination with metformin

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
2.5MG;1GM	TABLET, EXTENDED RELEASE;ORAL	Prescription
5MG;1GM	TABLET, EXTENDED RELEASE;ORAL	Prescription

51. Drug name - KALYDECO

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8883206	VERTEX PHARMS INC	Pharmaceutical composition and administrations thereof	Feb, 2033 (10 years from now)
US10272046	VERTEX PHARMS INC	Pharmaceutical composition and administrations thereof	Feb, 2033 (10 years from now)

Drugs and Companies using IVACAFTOR ingredient

Treatment: Treatment of cf in a patient age 6 months to <6 years who has one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in vitro assay data using the composition recited in claim 1 of us 10272046; treatment of cf in a patient age 4 months to <6 years who has one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in vitro assay data using the composition recited in claim 1 of us 10272046

Dosage: GRANULE;ORAL

Strength	Dosage	Availability
25MG/PACKET	GRANULE;ORAL	Prescription
50MG/PACKET	GRANULE;ORAL	Prescription
75MG/PACKET	GRANULE;ORAL	Prescription

52. Drug name - KENGREAL

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8680052	CHIESI	Methods of treating, reducing the incidence of, and/or preventing ischemic events	Mar, 2033 (10 years from now)

Drugs and Companies using CANGRELOR ingredient

Treatment: Method comprising iv administration of cangrelor before pci then continuous infusion for at least 2 hours or the duration of pci and, during or after continuous infusion, administration of a loading dose of ticagrelor, or an equivalent method

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
50MG/VIAL	POWDER;INTRAVENOUS	Prescription

53. Drug name - KORLYM

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10500216	CORCEPT THERAP	Optimizing mifepristone absorption	Mar, 2033 (10 years from now)

Drugs and Companies using MIFEPRISTONE ingredient

Treatment: Treating cushing's syndrome

Dosage: TABLET;ORAL

Strength	Dosage	Availability
300MG	TABLET;ORAL	Prescription

54. Drug name - KYPROLIS

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9493582	ONYX THERAP	Alkylated cyclodextrin compositions and processes for preparing and using the same	Feb, 2033 (10 years from now)

Drugs and Companies using CARFILZOMIB ingredient

Treatment: NA

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
10MG/VIAL	POWDER;INTRAVENOUS	Prescription
30MG/VIAL	POWDER;INTRAVENOUS	Prescription
60MG/VIAL	POWDER;INTRAVENOUS	Prescription

55. Drug name - LILETTA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11090186	MEDICINES360	Methods for using intrauterine systems and IUD insertion devices	Oct, 2033 (11 years from now)

Drugs and Companies using LEVONORGESTREL ingredient

Treatment: A method for prevention of pregnancy

Dosage: INTRAUTERINE DEVICE;INTRAUTERINE

Strength	Dosage	Availability
52MG	INTRAUTERINE DEVICE;INTRAUTERINE	Prescription

56. Drug name - LINZESS

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9708371	ALLERGAN	Treatments for gastrointestinal disorders	Aug, 2033 (10 years from now)

Drugs and Companies using LINACLOTIDE ingredient

Treatment: Method of treating irritable bowel syndrome with constipation in adult patients.; method of treating chronic idiopathic constipation in adult patients.

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
72MCG	CAPSULE;ORAL	Prescription
145MCG	CAPSULE;ORAL	Prescription
290MCG	CAPSULE;ORAL	Prescription

57. Drug name - LOKELMA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10695365	ASTRAZENECA	Microporous zirconium silicate for the treatment of hyperkalemia	Oct, 2033 (11 years from now)
US8877255	ASTRAZENECA	Microporous zirconium silicate for the treatment of hyperkalemia	Oct, 2033 (11 years from now)
US9913860	ASTRAZENECA	Microporous zirconium silicate for the treatment of hyperkalemia	Oct, 2033 (11 years from now)
CN104797263A	ASTRAZENECA	Microporous Zirconium Silicate For Treating Hyperpotassaemia	Oct, 2033 (11 years from now)
CN104797263B	ASTRAZENECA	For Curing Hyperpotassaemia Microporous Zirconium Silicate	Oct, 2033 (11 years from now)

Drugs and Companies using SODIUM ZIRCONIUM CYCLOSILICATE ingredient

Treatment: NA

Dosage: FOR SUSPENSION;ORAL

Strength	Dosage	Availability
5GM/PACKET	FOR SUSPENSION;ORAL	Prescription
10GM/PACKET	FOR SUSPENSION;ORAL	Prescription

58. Drug name - LONHALA MAGNAIR KIT

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9604018	SUNOVION RESP	Aerosol therapy device	May, 2033 (10 years from now)

Drugs and Companies using GLYCOPYRROLATE ingredient

Treatment: NA

Dosage: SOLUTION;INHALATION

Strength	Dosage	Availability
25MCG/ML	SOLUTION;INHALATION	Prescription

59. Drug name - LORBRENA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8680111	PFIZER	Macrocyclic derivatives for the treatment of diseases	Mar, 2033 (10 years from now)
CN104169286A	PFIZER	Macrocyclic Derivative For Treating Proliferative Diseases	Feb, 2033 (10 years from now)
CN104169286B	PFIZER	Macrocyclic Derivative For Treating Proliferative Diseases	Feb, 2033 (10 years from now)
IN201407205P4	PFIZER	Macrocyclic Derivatives For The Treatment Of Proliferative Diseases	Feb, 2033 (10 years from now)
IN298989B	PFIZER	Macrocyclic Derivatives For The Treatment Of Proliferative Diseases	Feb, 2033 (10 years from now)
EP2822953B1	PFIZER	Macrocyclic Derivatives For The Treatment Of Proliferative Diseases	Feb, 2033 (10 years from now)
EP2822953B9	PFIZER	Macrocyclic Derivatives For The Treatment Of Proliferative Diseases	Feb, 2033 (10 years from now)
EP2822953A1	PFIZER	Macrocyclic Derivatives For The Treatment Of Proliferative Diseases	Feb, 2033 (10 years from now)

Drugs and Companies using LORLATINIB ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
25MG	TABLET;ORAL	Prescription
100MG	TABLET;ORAL	Prescription

60. Drug name - LUZU

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9453006	BAUSCH	Crystalline form having specific crystal habit and pharmaceutical composition containing this crystalline form as active ingredient	Sep, 2033 (10 years from now)
US9199977	BAUSCH	Crystal having crystal habits and pharmaceutical composition obtained by processing the crystal	Sep, 2033 (10 years from now)
US9012484	BAUSCH	Crystal and pharmaceutical preparation containing the same crystal	Sep, 2033 (10 years from now)
CN105026390A	BAUSCH	Crystal Form With Specific Crystallization Habit Modifier And Drug Composition Containing Crystal Form As Active Ingredient	Jun, 2033 (10 years from now)
CN105026390B	BAUSCH	Crystal Form With Specific Crystallization Habit Modifier And Drug Composition Containing Crystal Form As Active Ingredient	Jun, 2033 (10 years from now)
EP2964641B1	BAUSCH	Crystalline Form Having Specific Crystal Habit And Pharmaceutical Composition Containing This Crystalline Form As Active Ingredient	Jun, 2033 (10 years from now)
EP2964641A1	BAUSCH	Crystalline Form Having Specific Crystal Habit And Pharmaceutical Composition Containing This Crystalline Form As Active Ingredient	Jun, 2033 (10 years from now)
EP2895165A1	BAUSCH	Crystal And Pharmaceutical Preparation Containing The Same Crystal	Sep, 2033 (10 years from now)
EP2895165B1	BAUSCH	Crystal And Pharmaceutical Preparation Containing The Same Crystal	Sep, 2033 (10 years from now)

Drugs and Companies using LULICONAZOLE ingredient

Treatment: NA

Dosage: CREAM;TOPICAL

Strength	Dosage	Availability
1%	CREAM;TOPICAL	Prescription

61. Drug name - LYMPHOSEEK KIT

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9439985	CARDINAL HEALTH 414	Compositions for radiolabeling diethylenetriaminepentaacetic acid (DTPA)-dextran	Sep, 2033 (10 years from now)

Drugs and Companies using TECHNETIUM TC-99M TILMANOCEPT ingredient

Treatment: NA

Dosage: INJECTABLE;INJECTION

Strength	Dosage	Availability
N/A	INJECTABLE;INJECTION	Prescription

62. Drug name - MEKINIST

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10869869	NOVARTIS	Method of adjuvant cancer treatment	Aug, 2033 (10 years from now)

Drugs and Companies using TRAMETINIB DIMETHYL SULFOXIDE ingredient

Treatment: Mekinist(r) is indicated, in combination with dabrafenib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations as detected by an fda-approved test, and involvement of lymph node(s), following complete resection

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 0.5MG	TABLET;ORAL	Prescription
EQ 1MG	TABLET;ORAL	Discontinued
EQ 2MG	TABLET;ORAL	Prescription

63. Drug name - MEKTOVI

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9562016	ARRAY BIOPHARMA INC	Preparation of and formulation comprising a MEK inhibitor	Oct, 2033 (11 years from now)
CN104870427B	ARRAY BIOPHARMA INC	Preparation And Formulation Comprising An Mek Inhibitor Of Mek Inhibitors	Oct, 2033 (11 years from now)
CN104870427A	ARRAY BIOPHARMA INC	Preparation Of Formulation Comprising Mek Inhibitor	Oct, 2033 (11 years from now)
IN201501287P2	ARRAY BIOPHARMA INC	Preparation Of And Formulation Comprising A Mek Inhibitor	Oct, 2033 (11 years from now)
IN334786B	ARRAY BIOPHARMA INC	Preparation Of And Formulation Comprising A Mek Inhibitor	Oct, 2033 (11 years from now)
EP2909182A4	ARRAY BIOPHARMA INC	Preparation Of And Formulation Comprising A Mek Inhibitor	Oct, 2033 (11 years from now)
EP2909182A1	ARRAY BIOPHARMA INC	Preparation Of And Formulation Comprising A Mek Inhibitor	Oct, 2033 (11 years from now)
EP2909182B1	ARRAY BIOPHARMA INC	Preparation Of And Formulation Comprising A Mek Inhibitor	Oct, 2033 (11 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9980944	ARRAY BIOPHARMA INC	Preparation of and formulation comprising a MEK inhibitor	Oct, 2033 (11 years from now)
US9598376	ARRAY BIOPHARMA INC	Preparation of and formulation comprising a MEK inhibitor	Oct, 2033 (11 years from now)

Drugs and Companies using BINIMETINIB ingredient

Treatment: Treatment of melanoma with a braf mutation; Method of treating melanoma

Dosage: TABLET;ORAL

Strength	Dosage	Availability
15MG	TABLET;ORAL	Prescription

64. Drug name - MITIGARE

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9399036	HIKMA INTL PHARMS	Methods of colchicine administration	Aug, 2033 (10 years from now)
US8927607	HIKMA INTL PHARMS	Methods of colchicine administration	Aug, 2033 (10 years from now)
US9675613	HIKMA INTL PHARMS	Methods of colchicine administration	Aug, 2033 (10 years from now)
US9789108	HIKMA INTL PHARMS	Methods of colchicine administration	Aug, 2033 (10 years from now)
US9555029	HIKMA INTL PHARMS	Methods of colchicine administration	Aug, 2033 (10 years from now)

Drugs and Companies using COLCHICINE ingredient

Treatment: Method of using colchicine for the prophylaxis of gout flares

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
0.6MG	CAPSULE;ORAL	Prescription

65. Drug name - NAFTIN

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10166206	SEBELA IRELAND LTD	Topical compositions and methods for making and using same	Jan, 2033 (10 years from now)
US8778365	SEBELA IRELAND LTD	Topical compositions and methods for making and using same	Jan, 2033 (10 years from now)
US10695303	SEBELA IRELAND LTD	Topical compositions and methods for making and using same	Jan, 2033 (10 years from now)
US10166205	SEBELA IRELAND LTD	Topical compositions and methods for making and using same	Jan, 2033 (10 years from now)
US10729667	SEBELA IRELAND LTD	Topical compositions and methods for making and using same	Jan, 2033 (10 years from now)
US9161914	SEBELA IRELAND LTD	Topical compositions and methods for making and using same	Jan, 2033 (10 years from now)

Drugs and Companies using NAFTIFINE HYDROCHLORIDE ingredient

Treatment: Treatment of fungal infections

Dosage: GEL;TOPICAL

Strength	Dosage	Availability
2%	GEL;TOPICAL	Prescription

66. Drug name - NOXAFIL

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9493582	MERCK SHARP DOHME	Alkylated cyclodextrin compositions and processes for preparing and using the same	Feb, 2033 (10 years from now)

Drugs and Companies using POSACONAZOLE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
300MG/16.7ML (18MG/ML)	SOLUTION;INTRAVENOUS	Prescription

67. Drug name - NURTEC ODT

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8759372	BIOHAVEN IRELAND	N-(5S,6S,9R)-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-ctclohepta[b]Pyridin-9-yl-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-carboxylate salt	Feb, 2033 (10 years from now)
CN104136437A	BIOHAVEN IRELAND	N - (5S, 6S, 9R) -4-(2-Oxo-3, -2 - Dihydro - -1H - Imidazo [4, 5-B-A] Naphthyridine - -1 - Yl) - Piperidine - -1 - Carboxylic Acid 5-Amino - -6-(2, 3 Phenyl) -6, 7, 8, 9-Tetrahydropyranyl -5H - Cyclohepta [B] -9 - Ester Hemisulfate	Feb, 2033 (10 years from now)
CN104136437B	BIOHAVEN IRELAND	N - (5S, 6S, 9R) -4-(2-Oxo-3, -2 - Dihydro - -1H - Imidazo [4, 5-B-A] Naphthyridine - -1 - Yl) - Piperidine - -1 - Carboxylic Acid 5-Amino - -6-(2, 3 Phenyl) -6, 7, 8, 9-Tetrahydropyranyl -5H - Cyclohepta [B] -9 - Ester Hemisulfate	Feb, 2033 (10 years from now)
EP2820016B1	BIOHAVEN IRELAND	N- (5S, 6S, 9R) - 5 -Amino- 6 - (2, 3 - Difluorophenyl) -6, 7, 8, 9 - Tetrahydro - 5H - Cyclohepta [B]Pyridin-9 -Yl- 4 - (2 - Oxo-2, 3 - Dihydro - 1H- Imidazo [4, 5 -B]Pyridin - 1 - Yl) Piperidine - 1 - Carboxylate, Hemisulfate Salt	Feb, 2033 (10 years from now)
EP2820016A1	BIOHAVEN IRELAND	N- (5S, 6S, 9R) - 5 -Amino- 6 - (2, 3 - Difluorophenyl) -6, 7, 8, 9 - Tetrahydro - 5H - Cyclohepta [B]Pyridin-9 -Yl- 4 - (2 - Oxo-2, 3 - Dihydro - 1H- Imidazo [4, 5 -B]Pyridin - 1 - Yl) Piperidine - 1 - Carboxylate, Hemisulfate Salt	Feb, 2033 (10 years from now)
EP3254681A1	BIOHAVEN IRELAND	N-(5S,6S,9R)-5-Amino-6-(2,3-Difluorophenyl)-6,7,8,9-Tetrahydro-5H-Cyclohepta[B]Pyridin-9-Yl-4-(2-Oxo-2,3-Dihydro-1H-Imidazo[4,5-B]Pyridin-1-Yl)Piperidine-1-Carboxylate Salt	Feb, 2033 (10 years from now)
EP3254681B1	BIOHAVEN IRELAND	N-(5S,6S,9R)-5-Amino-6-(2,3-Difluorophenyl)-6,7,8,9-Tetrahydro-5H-Cyclohepta[B]Pyridin-9-Yl-4-(2-Oxo-2,3-Dihydro-1H-Imidazo[4,5-B]Pyridin-1-Yl)Piperidine-1-Carboxylate Salt	Feb, 2033 (10 years from now)

Drugs and Companies using RIMEGEPANT SULFATE ingredient

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

Strength	Dosage	Availability
EQ 75MG BASE	TABLET, ORALLY DISINTEGRATING;ORAL	Prescription

68. Drug name - OCALIVA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10174073	INTERCEPT PHARMS INC	Preparation and uses of obeticholic acid	Jun, 2033 (10 years from now)
EP3336097A1	INTERCEPT PHARMS INC	Preparation Of The Non-Crystalline Form Of Obeticholic Acid	Jun, 2033 (10 years from now)
EP3336097B1	INTERCEPT PHARMS INC	Preparation Of The Non-Crystalline Form Of Obeticholic Acid	Jun, 2033 (10 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9238673	INTERCEPT PHARMS INC	Preparation and uses of obeticholic acid	Jun, 2033 (10 years from now)
US10047117	INTERCEPT PHARMS INC	Preparation and uses of obeticholic acid	Sep, 2033 (10 years from now)

Drugs and Companies using OBETICHOLIC ACID ingredient

Treatment: Treatment of primary biliary cholangitis (pbc)

Dosage: TABLET;ORAL

Strength	Dosage	Availability
5MG	TABLET;ORAL	Prescription
10MG	TABLET;ORAL	Prescription

69. Drug name - ODEFSEY

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8754065 (Pediatric)	GILEAD SCIENCES INC	Tenofovir alafenamide hemifumarate	Feb, 2033 (10 years from now)
US9296769 (Pediatric)	GILEAD SCIENCES INC	Tenofovir alafenamide hemifumarate	Feb, 2033 (10 years from now)

Drugs and Companies using EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
200MG;EQ 25MG BASE;EQ 25MG BASE	TABLET;ORAL	Prescription

70. Drug name - OMIDRIA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9486406	RAYNER SURGICAL	Stable preservative-free mydriatic and anti-inflammatory solutions for injection	Oct, 2033 (11 years from now)
US9066856	RAYNER SURGICAL	Stable preservative-free mydriatic and anti-inflammatory solutions for injection	Oct, 2033 (11 years from now)
US9855246	RAYNER SURGICAL	Stable preservative-free mydriatic and anti-inflammatory solutions for injection	Oct, 2033 (11 years from now)

Drugs and Companies using KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: SOLUTION;IRRIGATION

Strength	Dosage	Availability
EQ 0.3% BASE;EQ 1% BASE	SOLUTION;IRRIGATION	Prescription

71. Drug name - ONIVYDE

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9339497	IPSEN INC	Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan	Jun, 2033 (10 years from now)
US9717724	IPSEN INC	Methods for treating pancreatic cancer using combination therapies	Jun, 2033 (10 years from now)
US9492442	IPSEN INC	Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan	Jun, 2033 (10 years from now)
US9364473	IPSEN INC	Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan	Jun, 2033 (10 years from now)
US9452162	IPSEN INC	Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan	Jun, 2033 (10 years from now)
US10980795	IPSEN INC	Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan	Jun, 2033 (10 years from now)

Drugs and Companies using IRINOTECAN HYDROCHLORIDE ingredient

Treatment: Treatment of metastatic adenocarcinoma of the pancreas that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin; Treatment of metastatic adenocarcinoma of the pancreas that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin, in a patient not homozygous for the ugt1a1*28 allele; treatment of metastatic adenocarcinoma of the pancreas that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin; Treatment of exocrine pancreatic cancer that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin; treatment of pancreatic cancer that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin; treatment of metastatic adenocarcinoma of the pancreas that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin; Treatment of metastatic adenocarcinoma of the pancreas that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin, in a patient homozygous for the ugt1a1*28 allele; Treatment of pancreatic cancer that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin

Dosage: INJECTABLE, LIPOSOMAL;INTRAVENOUS

Strength	Dosage	Availability
EQ 43MG BASE/10ML (EQ 4.3MG BASE/ML)	INJECTABLE, LIPOSOMAL;INTRAVENOUS	Prescription

72. Drug name - ONZETRA XSAIL

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10478574	CURRAX	Nasal administration	Nov, 2033 (11 years from now)

Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient

Treatment: Method of delivering sumatriptan to a nasal cavity

Dosage: POWDER;NASAL

Strength	Dosage	Availability
EQ 11MG BASE	POWDER;NASAL	Prescription

73. Drug name - ORFADIN

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9301932	SWEDISH ORPHAN	Liquid pharmaceutical composition comprising nitisinone	Feb, 2033 (10 years from now)

Drugs and Companies using NITISINONE ingredient

Treatment: Treatment of hereditary tyrosinemia type 1 (ht-1) in combination with dietary restriction of tyrosine and phenylalanine

Dosage: SUSPENSION;ORAL

Strength	Dosage	Availability
4MG/ML	SUSPENSION;ORAL	Prescription

74. Drug name - OZEMPIC

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10335462	NOVO	Use of long-acting GLP-1 peptides	Jun, 2033 (10 years from now)

Drugs and Companies using SEMAGLUTIDE ingredient

Treatment: A method of treating type 2 diabetes comprising administering semaglutide once weekly in a amount of 1.0 mg to a subject in need thereof

Dosage: SOLUTION;SUBCUTANEOUS

Strength	Dosage	Availability
2MG/1.5ML (1.34MG/ML)	SOLUTION;SUBCUTANEOUS	Prescription
4MG/3ML (1.34MG/ML)	SOLUTION;SUBCUTANEOUS	Prescription

75. Drug name - PEMAZYRE

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10131667	INCYTE CORP	Substituted tricyclic compounds as FGFR inhibitors	Jun, 2033 (10 years from now)

Drugs and Companies using PEMIGATINIB ingredient

Treatment: For the treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or other rearrangement

Dosage: TABLET;ORAL

Strength	Dosage	Availability
4.5MG	TABLET;ORAL	Prescription
9MG	TABLET;ORAL	Prescription
13.5MG	TABLET;ORAL	Prescription

76. Drug name - PHENYLEPHRINE HYDROCHLORIDE

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8859623	PARAGON BIOTECK	Methods and compositions of stable phenylephrine formulations	Nov, 2033 (11 years from now)

Drugs and Companies using PHENYLEPHRINE HYDROCHLORIDE ingredient

Treatment: Dilation of the pupil

Dosage: SOLUTION/DROPS;OPHTHALMIC

Strength	Dosage	Availability
2.5%	SOLUTION/DROPS;OPHTHALMIC	Prescription
10%	SOLUTION/DROPS;OPHTHALMIC	Prescription

77. Drug name - PHEXXI

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10568855	EVOFEM INC	Compositions and methods for enhancing the efficacy of contraceptive microbicides	Mar, 2033 (10 years from now)

Drugs and Companies using CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE ingredient

Treatment: Prevention of pregnancy

Dosage: GEL;VAGINAL

Strength	Dosage	Availability
1%;1.8%;0.4%	GEL;VAGINAL	Prescription

78. Drug name - PICATO

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9789078	LEO LABS	Method of topically treating actinic keratosis with ingenol mebutate cycle therapy	May, 2033 (10 years from now)

Drugs and Companies using INGENOL MEBUTATE ingredient

Treatment: Topical treatment of actinic keratosis of the face or scalp using more than one treatment course of ingenol mebutate

Dosage: GEL;TOPICAL

Strength	Dosage	Availability
0.015%	GEL;TOPICAL	Discontinued
0.05%	GEL;TOPICAL	Discontinued

79. Drug name - PLENVU

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9707297	SALIX	Compositions	Sep, 2033 (10 years from now)
US8999313	SALIX	Compositions	Sep, 2033 (10 years from now)
US9326969	SALIX	Compositions	Sep, 2033 (10 years from now)
US10918723	SALIX	Colon cleansing compositions and methods of use	Sep, 2033 (10 years from now)
US10016504	SALIX	Compositions	Sep, 2033 (10 years from now)

Drugs and Companies using ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE ingredient

Treatment: For cleansing of the colon in preparation for colonoscopy in adults

Dosage: FOR SOLUTION;ORAL

Strength	Dosage	Availability
7.54GM;140GM;2.2GM;48.11GM;5.2GM;9GM	FOR SOLUTION;ORAL	Prescription

80. Drug name - PREVYMIS

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10603384	MERCK SHARP DOHME	Pharmaceutical composition containing an antivirally active dihydroquinazoline derivative	Feb, 2033 (10 years from now)

Drugs and Companies using LETERMOVIR ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
240MG/12ML (20MG/ML)	SOLUTION;INTRAVENOUS	Prescription
480MG/24ML (20MG/ML)	SOLUTION;INTRAVENOUS	Prescription

81. Drug name - PROLENSA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9517220	BAUSCH AND LOMB	Bromfenac bioavailability	Nov, 2033 (11 years from now)

Drugs and Companies using BROMFENAC SODIUM ingredient

Treatment: Treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery

Dosage: SOLUTION/DROPS;OPHTHALMIC

Strength	Dosage	Availability
EQ 0.07% ACID	SOLUTION/DROPS;OPHTHALMIC	Prescription

82. Drug name - QBREXZA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10548875	JOURNEY	Glycopyrrolate salts	Feb, 2033 (10 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9259414	JOURNEY	Glycopyrrolate salts	Feb, 2033 (10 years from now)
US8859610	JOURNEY	Crystalline glycopyrrolate tosylate	Feb, 2033 (10 years from now)
US10543192	JOURNEY	Glycopyrrolate salts	Feb, 2033 (10 years from now)
US10004717	JOURNEY	Glycopyrrolate salts	Feb, 2033 (10 years from now)

Drugs and Companies using GLYCOPYRRONIUM TOSYLATE ingredient

Treatment: Topical treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older

Dosage: CLOTH;TOPICAL

Strength	Dosage	Availability
EQ 2.4% BASE	CLOTH;TOPICAL	Prescription

83. Drug name - QELBREE

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9662338	SUPERNUS PHARMS	Formulations of viloxazine	Feb, 2033 (10 years from now)
US9358204	SUPERNUS PHARMS	Formulations of viloxazine	Feb, 2033 (10 years from now)
US9603853	SUPERNUS PHARMS	Formulations of viloxazine	Feb, 2033 (10 years from now)

Drugs and Companies using VILOXAZINE HYDROCHLORIDE ingredient

Treatment: For the treatment of attention deficit hyperactivity disorder (adhd)

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
EQ 100MG BASE	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
EQ 150MG BASE	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
EQ 200MG BASE	CAPSULE, EXTENDED RELEASE;ORAL	Prescription

84. Drug name - QUDEXY XR

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8889190	UPSHER SMITH LABS	Extended-release topiramate capsules	Mar, 2033 (10 years from now)
US10363224	UPSHER SMITH LABS	Extended-release topiramate capsules	Mar, 2033 (10 years from now)
US8652527	UPSHER SMITH LABS	Extended-release topiramate capsules	Mar, 2033 (10 years from now)
US9555005	UPSHER SMITH LABS	Extended-release topiramate capsules	Mar, 2033 (10 years from now)
US9101545	UPSHER SMITH LABS	Extended-release topiramate capsules	Mar, 2033 (10 years from now)

Drugs and Companies using TOPIRAMATE ingredient

Treatment: Treatment of seizures

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
25MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
50MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
100MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
150MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
200MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription

85. Drug name - QUILLICHEW ER

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11103494	NEXTWAVE PHARMS	Methylphenidate extended release chewable tablet	Aug, 2033 (10 years from now)
US10857143	NEXTWAVE PHARMS	Methylphenidate extended release chewable tablet	Aug, 2033 (10 years from now)
US11103495	NEXTWAVE PHARMS	Methylphenidate extended release chewable tablet	Aug, 2033 (10 years from now)
US9844544	NEXTWAVE PHARMS	Methylphenidate extended release chewable tablet	Aug, 2033 (10 years from now)
US9295642	NEXTWAVE PHARMS	Methylphenidate extended release chewable tablet	Aug, 2033 (10 years from now)
US8999386	NEXTWAVE PHARMS	Methylphenidate extended release chewable tablet	Aug, 2033 (10 years from now)
US9545399	NEXTWAVE PHARMS	Methylphenidate extended release chewable tablet	Aug, 2033 (10 years from now)

Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient

Treatment: A method for treating a subject having adhd, said method comprising orally administering to said subject a racemic methylphenidate chewable tablet as claimed; A method of providing a subject with a therapeutically effective amount of racemic methylphenidate by orally administering to said subject a single methylphenidate extended release chewable tablet as claimed; A method of providing a subject with therapeutically effective amount of racemic methylphenidate by orally administering to said subject a single methylphenidate extended release chewable tablet according to claim 1

Dosage: TABLET, EXTENDED RELEASE, CHEWABLE;ORAL

Strength	Dosage	Availability
20MG	TABLET, EXTENDED RELEASE, CHEWABLE;ORAL	Prescription
30MG	TABLET, EXTENDED RELEASE, CHEWABLE;ORAL	Prescription
40MG	TABLET, EXTENDED RELEASE, CHEWABLE;ORAL	Prescription

86. Drug name - QULIPTA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9850246	ABBVIE INC	Process for making CGRP receptor antagonists	Mar, 2033 (10 years from now)
EP2849568A1	ABBVIE INC	Process For Making Cgrp Receptor Antagonists	Mar, 2033 (10 years from now)
EP2849568B1	ABBVIE INC	Process For Making Cgrp Receptor Antagonists	Mar, 2033 (10 years from now)
EP2849568A4	ABBVIE INC	Process For Making Cgrp Receptor Antagonists	Mar, 2033 (10 years from now)

Drugs and Companies using ATOGEPANT ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
10MG	TABLET;ORAL	Prescription
30MG	TABLET;ORAL	Prescription
60MG	TABLET;ORAL	Prescription

87. Drug name - REZUROCK

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10696660	KADMON PHARMS LLC	Rho kinase inhibitors	Oct, 2033 (11 years from now)
US9815820	KADMON PHARMS LLC	Rho kinase inhibitors	Oct, 2033 (11 years from now)
US10183931	KADMON PHARMS LLC	Rho kinase inhibitors	Oct, 2033 (11 years from now)

Drugs and Companies using BELUMOSUDIL MESYLATE ingredient

Treatment: For the treatment of chronic graft versus host disease; For the treatment of chronic graft versus hold disease

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 200MG BASE	TABLET;ORAL	Prescription

88. Drug name - ROSZET

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10376470	ALTHERA PHARMS	Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases	May, 2033 (10 years from now)
US9763885	ALTHERA PHARMS	Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases	May, 2033 (10 years from now)

Drugs and Companies using EZETIMIBE; ROSUVASTATIN CALCIUM ingredient

Treatment: Treatment of hyperlipidemia

Dosage: TABLET;ORAL

Strength	Dosage	Availability
10MG;EQ 5MG BASE	TABLET;ORAL	Prescription
10MG;EQ 10MG BASE	TABLET;ORAL	Prescription
10MG;EQ 20MG BASE	TABLET;ORAL	Prescription
10MG;EQ 40MG BASE	TABLET;ORAL	Prescription

89. Drug name - ROZLYTREK

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9085565	GENENTECH INC	Process for the preparation of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide	May, 2033 (10 years from now)
CN104395308B	GENENTECH INC	N - [3 - (5, 5-Difluoro-Benzyl)--1H - Indazole - -3 - Yl] -4-(4-Methyl-Piperazine - -1 - Yl)--2-(Tetrahydro-Pyran - -4 - Ylamino) - Benzamide Preparation Method	May, 2033 (10 years from now)
CN104395308A	GENENTECH INC	N - [3 - (5, 5-Difluoro-Benzyl)--1H - Indazole - -3 - Yl] -4-(4-Methyl-Piperazine - -1 - Yl)--2-(Tetrahydro-Pyran - -4 - Ylamino) - Benzamide Preparation Method	May, 2033 (10 years from now)
IN201409107P4	GENENTECH INC	Process For The Preparation Of N [5 (3 5 Difluoro Benzyl) 1H Indazol 3 Yl] 4 (4 Methyl Piperazin 1 Yl) 2 (Tetrahydro Pyran 4 Ylamino) Benzamide	May, 2033 (10 years from now)
IN361050B	GENENTECH INC	Process For The Preparation Of N-[5-(3-5-Difluoro Benzyl)-1H-Indazol 3 Yl]- 4-(4 Methyl Piperazin -1- Yl) -2- (Tetrahydro Pyran -4- Ylamino) Benzamide	May, 2033 (10 years from now)
EP3333166A1	GENENTECH INC	Process For The Preparation Of N-[5-(3,5-Difluoro-Benzyl)-1H-Indazol-3-Yl]-4-(4-Methyl-Piperazin-1-Yl)-2-(Tetrahydro-Pyran-4-Ylamino)-Benzamide	May, 2033 (10 years from now)
EP3290414B1	GENENTECH INC	Crystalline Form Of N-[5-(3,5-Difluoro-Benzyl)-1H-Indazol-3-Yl]-4-(4-Methyl-Piperazin-1-Yl)-2-(Tetrahydro-Pyran-4-Ylamino)-Benzamide	May, 2033 (10 years from now)
EP3333166B1	GENENTECH INC	Process For The Preparation Of N-[5-(3,5-Difluoro-Benzyl)-1H-Indazol-3-Yl]-4-(4-Methyl-Piperazin-1-Yl)-2-(Tetrahydro-Pyran-4-Ylamino)-Benzamide	May, 2033 (10 years from now)
EP3290414A1	GENENTECH INC	Crystalline Form Of N-[5-(3,5-Difluoro-Benzyl)-1H-Indazol-3-Yl]-4-(4-Methyl-Piperazin-1-Yl)-2-(Tetrahydro-Pyran-4-Ylamino)-Benzamide	May, 2033 (10 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9649306	GENENTECH INC	Treatment of diseases through administration of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide	May, 2033 (10 years from now)

Drugs and Companies using ENTRECTINIB ingredient

Treatment: Treatment of solid tumors that have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion; treatment of ros1-positive non-small cell lung cancer

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
100MG	CAPSULE;ORAL	Prescription
200MG	CAPSULE;ORAL	Prescription

90. Drug name - RYBELSUS

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10933120	NOVO	Compositions of GLP-1 peptides and preparation thereof	Mar, 2033 (10 years from now)

Drugs and Companies using SEMAGLUTIDE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
3MG	TABLET;ORAL	Prescription
7MG	TABLET;ORAL	Prescription
14MG	TABLET;ORAL	Prescription

91. Drug name - SCEMBLIX

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8829195	NOVARTIS	Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1	May, 2033 (10 years from now)
CN104302638B	NOVARTIS	Benzamide Derivatives For Inhibiting The Activity Of Abl1, Abl2 And Bcr-Abl1	May, 2033 (10 years from now)
CN104302638A	NOVARTIS	Benzamide Derivatives For Inhibiting The Activity Of Abl1, Abl2 And Bcr-Abl1	May, 2033 (10 years from now)
CN104302634A	NOVARTIS	Benzamide Derivatives For Inhibiting The Activity Of Abl1, Abl2 And Bcr-Abl1	May, 2033 (10 years from now)
CN104302634B	NOVARTIS	For Inhibiting Activity Of Abl1, Abl2, And Bcr-Abl1 Of Benzamide Derivatives	May, 2033 (10 years from now)
EP2861579B9	NOVARTIS	Benzamide Derivatives For Inhibiting The Activity Of Abl1, Abl2 And Bcr-Abl1	May, 2033 (10 years from now)
EP2861576B1	NOVARTIS	Benzamide Derivatives For Inhibiting The Activity Of Abl1, Abl2 And Bcr-Abl1	May, 2033 (10 years from now)
EP2861579A1	NOVARTIS	Benzamide Derivatives For Inhibiting The Activity Of Abl1, Abl2 And Bcr-Abl1	May, 2033 (10 years from now)
EP2861579B1	NOVARTIS	Benzamide Derivatives For Inhibiting The Activity Of Abl1, Abl2 And Bcr-Abl1	May, 2033 (10 years from now)
EP2861576A1	NOVARTIS	Benzamide Derivatives For Inhibiting The Activity Of Abl1, Abl2 And Bcr-Abl1	May, 2033 (10 years from now)

Drugs and Companies using ASCIMINIB HYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 20MG BASE	TABLET;ORAL	Prescription
EQ 40MG BASE	TABLET;ORAL	Prescription

92. Drug name - SECUADO

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10022445	HISAMITSU	Patch	Jul, 2033 (10 years from now)
US9687474	HISAMITSU	Patch	Jul, 2033 (10 years from now)
US10814002	HISAMITSU	Patch and method for producing the same	Jul, 2033 (10 years from now)
US10583121	HISAMITSU	Patch	Jul, 2033 (10 years from now)
US11123305	HISAMITSU	Patch	Jul, 2033 (10 years from now)

Drugs and Companies using ASENAPINE ingredient

Treatment: Method of treating adults with schizophrenia comprising administering asenapine via a transdermal patch

Dosage: SYSTEM;TRANSDERMAL

Strength	Dosage	Availability
3.8MG/24HR	SYSTEM;TRANSDERMAL	Prescription
5.7MG/24HR	SYSTEM;TRANSDERMAL	Prescription
7.6MG/24HR	SYSTEM;TRANSDERMAL	Prescription

93. Drug name - SESQUIENT

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9493582	LUPIN	Alkylated cyclodextrin compositions and processes for preparing and using the same	Feb, 2033 (10 years from now)

Drugs and Companies using FOSPHENYTOIN SODIUM ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
EQ 100MG PHENYTOIN NA/2ML (EQ 50MG PHENYTOIN NA/ML)	SOLUTION;INTRAVENOUS	Discontinued
EQ 500MG PHENYTOIN NA/10ML (EQ 50MG PHENYTOIN NA/ML)	SOLUTION;INTRAVENOUS	Discontinued

94. Drug name - SEYSARA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9255068	ALMIRALL	Crystalline salts of (4S,4AS,5AR,12AS)-4-dimethylamino-3,10,12,12A-tetrahydroxy-7-[methoxy(methyl)amino)-methyl] acid amide and methods of using the same	Feb, 2033 (10 years from now)

Drugs and Companies using SARECYCLINE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 60MG BASE	TABLET;ORAL	Prescription
EQ 100MG BASE	TABLET;ORAL	Prescription
EQ 150MG BASE	TABLET;ORAL	Prescription

95. Drug name - SOAANZ

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10154963	SARFE PHARMS	Controlled-release formulations comprising Torsemide	Oct, 2033 (11 years from now)

Drugs and Companies using TORSEMIDE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
20MG	TABLET;ORAL	Prescription
40MG	TABLET;ORAL	Prescription
60MG	TABLET;ORAL	Prescription

96. Drug name - STRIBILD

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039718 (Pediatric)	GILEAD SCIENCES INC	Use of solid carrier particles to improve the processability of a pharmaceutical agent	Apr, 2033 (10 years from now)

Drugs and Companies using COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
150MG;150MG;200MG;300MG	TABLET;ORAL	Prescription

97. Drug name - SYMDEKO (COPACKAGED)

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10058546	VERTEX PHARMS INC	Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxo1-5-y1)-N-(1-(2,3-dihydroxypropy1)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-y1)-1H-indol-5-y1) cyclopropanecarbox-amide and administration thereof	Jul, 2033 (10 years from now)
US9012496	VERTEX PHARMS INC	Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof	Jul, 2033 (10 years from now)

Drugs and Companies using IVACAFTOR; IVACAFTOR, TEZACAFTOR ingredient

Treatment: Treatment of cystic fibrosis in patients 12 years and older, with a f508del or g551d cftr gene mutation and a a455e, 2789+5g->a, or 3849+10kbc->t mutation, comprising concurrent coadministration of the compositions of claim 1 of u.s patent 10058546; treatment of cystic fibrosis in patients 6 years and older, with a f508del or g551d cftr gene mutation and a a455e, 2789+5g->, or 3849+10kbc->t mutation, comprising concurrent coadministration of the compositions of claim 1 of u.s. patent 10058546; treatment of cf in patients 6 years and older who have a f508del or g551d cftr mutation and a 2nd mutation selected from r117h, a455e, 2789+5g->a, and 3849+10kbc->t, comprising concurrent coadministration of the compositions of claim 1 of us 10058546; treatment of cf in patients 12 years and older who have a f508del or g551d cftr mutation and a 2nd mutation selected from r117h, a455e, 2789+5g->a, & 3849+10kbc->t, comprising concurrent coadministration of the compositions of claim 1 of us 10058546; Tezacaftor and ivacaftor for the treatment of cystic fibrosis in patients who are homozygous for the f508del mutation or heterozygous for the f508del mutation and a second mutation that is responsive to tezacaftor/ivacaftor

Dosage: TABLET;ORAL

Strength	Dosage	Availability
75MG;75MG, 50MG	TABLET;ORAL	Prescription
150MG;150MG, 100MG	TABLET;ORAL	Prescription

98. Drug name - SYMPROIC

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10952968	BDSI	Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives	May, 2033 (10 years from now)
EP2851075A4	BDSI	Preparation Containing 6,7-Unsaturated-7-Carbamoylmorphinan Derivative	May, 2033 (10 years from now)
EP2851075B1	BDSI	Preparation Containing 6,7-Unsaturated-7-Carbamoylmorphinan Derivative	May, 2033 (10 years from now)
EP2851075A1	BDSI	Preparation Containing 6,7-Unsaturated-7-Carbamoylmorphinan Derivative	May, 2033 (10 years from now)

Drugs and Companies using NALDEMEDINE TOSYLATE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 0.2MG BASE	TABLET;ORAL	Prescription

99. Drug name - TAFINLAR

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10869869	NOVARTIS	Method of adjuvant cancer treatment	Aug, 2033 (10 years from now)

Drugs and Companies using DABRAFENIB MESYLATE ingredient

Treatment: Tafinlar(r) is indicated, in combination with trametinib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations as detected by an fda-approved test, and involvement of lymph node(s), following complete resection

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
EQ 50MG BASE	CAPSULE;ORAL	Prescription
EQ 75MG BASE	CAPSULE;ORAL	Prescription

100. Drug name - TAZVERIK

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9394283	EPIZYME INC	Salt form of a human histone methyltransferase EZH2 inhibitor	Apr, 2033 (10 years from now)
US10821113	EPIZYME INC	Salt form of a human histone methyltransferase EZH2 inhibitor	Apr, 2033 (10 years from now)
CN104603130A	EPIZYME INC	Salt Forms Of Human Histone Methyltransferase Ezh2 Inhibitor	Apr, 2033 (10 years from now)
CN104603130B	EPIZYME INC	A Salt Form Of Histone Methyltransferase Ezh2 Inhibitor	Apr, 2033 (10 years from now)
CN108358899B	EPIZYME INC	Salt Form Of Human Histone Methyltransferase Ezh2 Inhibitor	Apr, 2033 (10 years from now)
CN108358899A	EPIZYME INC	Human Salt Form Transmethylase Ezh2 Inhibitor Of	Apr, 2033 (10 years from now)
EP2836491B1	EPIZYME INC	Salt Form Of A Human Histone Methyltransferase Ezh2 Inhibitor	Apr, 2033 (10 years from now)
EP3184523A1	EPIZYME INC	N-((4,6-Dimethyl-2-Oxo-L,2-Dihydropyridin-3-Yl)Methyl)-5-(Ethyl (Tetrahydro-2H-Pyran-4-Yl)Amino)-4-Methyl-4'-(Morpholinomethyl)-[L,1'-Biphenyl]-3-Carboxamide Hydrobromide For Use In The Treatment Of A Cell Proliferative Disorder Of The Hematologic System	Apr, 2033 (10 years from now)
EP2836491A4	EPIZYME INC	Salt Form Of A Human Hi Stone Methyltransf Erase Ezh2 Inhibitor	Apr, 2033 (10 years from now)
EP3184523B1	EPIZYME INC	N-((4,6-Dimethyl-2-Oxo-L,2-Dihydropyridin-3-Yl)Methyl)-5-(Ethyl (Tetrahydro-2H-Pyran-4-Yl)Amino)-4-Methyl-4'-(Morpholinomethyl)-[L,1'-Biphenyl]-3-Carboxamide Hydrobromide For Use In The Treatment Of A Cell Proliferative Disorder Of The Hematologic System	Apr, 2033 (10 years from now)
EP2836491A1	EPIZYME INC	Salt Form Of A Human Histone Methyltransferase Ezh2 Inhibitor	Apr, 2033 (10 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9872862	EPIZYME INC	Salt form of a human histone methyltransferase EZH2 inhibitor	Apr, 2033 (10 years from now)
US10245269	EPIZYME INC	Salt form of a human histone methyltransferase EZH2 inhibitor	Apr, 2033 (10 years from now)

Drugs and Companies using TAZEMETOSTAT HYDROBROMIDE ingredient

Treatment: Method of treating a lung metastasis of epithelioid sarcoma; Method of treating epithelioid sarcoma by inhibiting enhancer of zeste homolog 2 (ezh2); method of treating relapsed or refractory follicular lymphoma positive for an enhancer of zeste homolog 2 (ezh2) mutation by inhibiting ezh2; method of treating relapsed or refractory follicular lymphoma by inhibiting ezh2

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 200MG BASE	TABLET;ORAL	Prescription

101. Drug name - TIBSOVO

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9850277	SERVIER	Therapeutically active compositions and their methods of use	Jan, 2033 (10 years from now)
US9474779	SERVIER	Therapeutically active compositions and their methods of use	Aug, 2033 (10 years from now)
IN338474B	SERVIER	Therapeutically Active Compositions And Their Methods Of Use	Jan, 2033 (10 years from now)
IN201405986P1	SERVIER	Therapeutically Active Compounds And Their Methods Of Use	Jan, 2033 (10 years from now)
EP2804851B1	SERVIER	Lactam Derivates Useful As Inhibitors Of Mutant Idh1	Jan, 2033 (10 years from now)
EP2804851A4	SERVIER	Therapeutically Active Compounds And Their Methods Of Use	Jan, 2033 (10 years from now)
EP3447052B1	SERVIER	Methods Of Preparing New Idh1 Inhibitors	Jan, 2033 (10 years from now)
EP3447052A1	SERVIER	Methods Of Preparing New Idh1 Inhibitors	Jan, 2033 (10 years from now)
EP2804851A1	SERVIER	Lactam Derivates Useful As Inhibitors Of Mutant Idh1	Jan, 2033 (10 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10717764	SERVIER	Therapeutically active compounds and their methods of use	Jan, 2033 (10 years from now)

Drugs and Companies using IVOSIDENIB ingredient

Treatment: A method of treating previously treated, locally advanced or metastatic cholangiocarcinoma characterized by an idh1 mutation

Dosage: TABLET;ORAL

Strength	Dosage	Availability
250MG	TABLET;ORAL	Prescription

102. Drug name - TIGECYCLINE

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9855335	AMNEAL	Tigecycline composition for injection	Apr, 2033 (10 years from now)

Drugs and Companies using TIGECYCLINE ingredient

Treatment: NA

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
50MG/VIAL	POWDER;INTRAVENOUS	Prescription

103. Drug name - TOLSURA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10463740	MAYNE PHARMA INTL	Itraconazole compositions and dosage forms, and methods of using the same	Jun, 2033 (10 years from now)
US9272046	MAYNE PHARMA INTL	Itraconazole compositions and dosage forms, and methods of using the same	Jun, 2033 (10 years from now)
US8921374	MAYNE PHARMA INTL	Itraconazole compositions and dosage forms, and methods of using the same	Jun, 2033 (10 years from now)
US10806792	MAYNE PHARMA INTL	Itraconazole compositions and dosage forms, and methods of using the same	Jun, 2033 (10 years from now)
US9713642	MAYNE PHARMA INTL	Itraconazole compositions and dosage forms, and methods of using the same	Jun, 2033 (10 years from now)

Drugs and Companies using ITRACONAZOLE ingredient

Treatment: Treatment of fungal infections, including blastomycosis, histoplasmosis, and aspergillosis

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
65MG	CAPSULE;ORAL	Prescription

104. Drug name - TRIKAFTA (COPACKAGED)

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9012496	VERTEX PHARMS INC	Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof	Jul, 2033 (10 years from now)

Drugs and Companies using ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR ingredient

Treatment: Treatment of cystic fibrosis in patients aged 12 years and older who have at least one f508del mutation in the cftr gene with a composition comprising elexacaftor, tezacaftor, and ivacaftor; and another composition comprising ivacaftor; treatment of cystic fibrosis in patients aged 6 years and older who have at least one f508del mutation in the cftr gene with a composition comprising elexacaftor, tezacaftor, and ivacaftor; and another composition comprising ivacaftor

Dosage: TABLET;ORAL

Strength	Dosage	Availability
50MG,37.5MG,25MG; 75MG	TABLET;ORAL	Prescription
100MG,75MG,50MG; 150MG	TABLET;ORAL	Prescription

105. Drug name - TRUDHESA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10940278	IMPEL NEUROPHARMA	Nozzles for nasal drug delivery	Jan, 2033 (10 years from now)
US9919117	IMPEL NEUROPHARMA	Nozzles for nasal drug delivery	Mar, 2033 (10 years from now)

Drugs and Companies using DIHYDROERGOTAMINE MESYLATE ingredient

Treatment: Nasal administration of dihydroergotamine mesylate by metered spray for the acute treatment of migraine with or without aura

Dosage: SPRAY, METERED;NASAL

Strength	Dosage	Availability
0.725MG/SPRAY	SPRAY, METERED;NASAL	Prescription

106. Drug name - TURALIO

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9358235	DAIICHI SANKYO INC	Kinase modulation, and indications therefor	Jun, 2033 (10 years from now)

Drugs and Companies using PEXIDARTINIB HYDROCHLORIDE ingredient

Treatment: Treatment of adult patients with symptomatic tenosynovial giant cell tumor (tgct) associated with severe morbidity or functional limitations and not amenable to improvement with surgery

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
EQ 200MG BASE	CAPSULE;ORAL	Prescription

107. Drug name - TYBOST

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039718 (Pediatric)	GILEAD SCIENCES INC	Use of solid carrier particles to improve the processability of a pharmaceutical agent	Apr, 2033 (10 years from now)

Drugs and Companies using COBICISTAT ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
150MG	TABLET;ORAL	Prescription

108. Drug name - UKONIQ

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9150579	TG THERAPS	Selective PI3K delta inhibitors	Jul, 2033 (10 years from now)
US10570142	TG THERAPS	Selective PI3K delta inhibitors	Jul, 2033 (10 years from now)
CN104470923B	TG THERAPS	Selective Pi3K Inhibitor	Jul, 2033 (10 years from now)
CN104470923A	TG THERAPS	Selective Pi3K Inhibitor	Jul, 2033 (10 years from now)
IN358166B	TG THERAPS	Selective Pi3K Delta Inhibitors	Jul, 2033 (10 years from now)
IN201500204P4	TG THERAPS	Selective Pi3K Delta Inhibitors	Jul, 2033 (10 years from now)
EP3260455A1	TG THERAPS	Selective Pi3K Delta Inhibitors	Jul, 2033 (10 years from now)
EP2870157B1	TG THERAPS	Selective Pi3K Delta Inhibitors	Jul, 2033 (10 years from now)
EP3260455B1	TG THERAPS	Selective Pi3K Delta Inhibitors	Jul, 2033 (10 years from now)
EP2870157A1	TG THERAPS	Selective Pi3K Delta Inhibitors	Jul, 2033 (10 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10072013	TG THERAPS	Selective PI3K delta inhibitors	Jul, 2033 (10 years from now)
US10981919	TG THERAPS	Selective PI3K delta inhibitors	Jul, 2033 (10 years from now)
US9669033	TG THERAPS	Selective PI3K delta inhibitors	Jul, 2033 (10 years from now)

Drugs and Companies using UMBRALISIB TOSYLATE ingredient

Treatment: Relapsed or refractory marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based regimen; relapsed or refractory follicular lymphoma (fl) who have received at least three prior lines of systemic therapy

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 200MG BASE	TABLET;ORAL	Prescription

109. Drug name - ULTRAVATE

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8962028	SUN PHARM INDUSTRIES	Topical steroid composition and method	Jun, 2033 (10 years from now)

Drugs and Companies using HALOBETASOL PROPIONATE ingredient

Treatment: Use of a lotion containing halobetasol propionate for the treatment of corticosteroid-responsive dermatoses including psoriasis

Dosage: LOTION;TOPICAL

Strength	Dosage	Availability
0.05%	LOTION;TOPICAL	Prescription

110. Drug name - VASCEPA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9610272	AMARIN PHARMS	Methods of reducing the risk of a cardiovascular event in a subject on statin therapy	Jun, 2033 (10 years from now)
US11000499	AMARIN PHARMS	Methods of reducing the risk of cardiovascular events in a subject	Jun, 2033 (10 years from now)
US10894028	AMARIN PHARMS	Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease	Jun, 2033 (10 years from now)
US10786478	AMARIN PHARMS	Methods of reducing the risk of cardiovascular events in a subject	Jun, 2033 (10 years from now)
US10792270	AMARIN PHARMS	Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease	Jun, 2033 (10 years from now)
US10576054	AMARIN PHARMS	Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease	Jun, 2033 (10 years from now)
US10668042	AMARIN PHARMS	Methods of reducing the risk of cardiovascular events in a subject	Jun, 2033 (10 years from now)
US10568861	AMARIN PHARMS	Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease	Jun, 2033 (10 years from now)
US10555924	AMARIN PHARMS	Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease	Jun, 2033 (10 years from now)
US10555925	AMARIN PHARMS	Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease	Jun, 2033 (10 years from now)
US10383840	AMARIN PHARMS	Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease	Jun, 2033 (10 years from now)
US10278936	AMARIN PHARMS	Methods of reducing the risk of a cardiovascular event in a subject on statin therapy	Jun, 2033 (10 years from now)
US10278937	AMARIN PHARMS	Methods of reducing the risk of a cardiovascular event in a subject on statin therapy	Jun, 2033 (10 years from now)
US10278935	AMARIN PHARMS	Methods of reducing the risk of a cardiovascular event in a subject on statin therapy	Jun, 2033 (10 years from now)
US9918954	AMARIN PHARMS	Methods of reducing the risk of a cardiovascular event in a subject on statin therapy	Jun, 2033 (10 years from now)
US9693986	AMARIN PHARMS	Methods of reducing the risk of a cardiovascular event in a subject on statin therapy	Jun, 2033 (10 years from now)
US9693985	AMARIN PHARMS	Methods of reducing the risk of a cardiovascular event in a subject on statin therapy	Jun, 2033 (10 years from now)
US9693984	AMARIN PHARMS	Methods of reducing the risk of a cardiovascular event in a subject on statin therapy	Jun, 2033 (10 years from now)
US9623001	AMARIN PHARMS	Methods of reducing the risk of a cardiovascular event in a subject on statin therapy	Jun, 2033 (10 years from now)
US9603826	AMARIN PHARMS	Methods of reducing the risk of a cardiovascular event in a subject on statin therapy	Jun, 2033 (10 years from now)
US11116742	AMARIN PHARMS	Methods of reducing the risk of cardiovascular events in a subject	Jun, 2033 (10 years from now)

Drugs and Companies using ICOSAPENT ETHYL ingredient

Treatment: Use of vascepa as an adjunct to statin therapy to reduce the risk of cardiovascular death and/or unstable angina in an adult patient with elevated triglyceride levels (tg >= 150 mg/dl to about 500 mg/dl); Use of vascepa as an adjunct to statin therapy to reduce the risk of a second and further cardiovascular event in an adult patient with established cardiovascular disease; Use of vascepa as an adjunct to statin therapy to reduce the risk of myocardial infarction in an adult patient with elevated triglyceride levels and established cv disease or diabetes mellitus and two or more additional risk factors for cv disease; Use of vascepa as an adjunct to statin therapy to reduce the risk of a third and further cardiovascular event in an adult patient with elevated tg levels (>=150 mg/dl) and established cardiovascular disease; use of vascepa as an adjunct to statin therapy to reduce the risk of a second or further cardiovascular (cv) event in an adult patient with elevated tg levels (>= 150 mg/dl) and diabetes mellitus and 2 or more additional risk factors for cv disease; Use of vascepa as an adjunct to statin therapy to reduce the risk of coronary revascularization in an adult patient with established cardiovascular disease; Use of vascepa as an adjunct to statin therapy to reduce the risk of a major cardiovascular event in an adult patient with diabetes mellitus and two or more additional risk factors for cardiovascular disease; Use of vascepa with high intensity statin therapy to reduce the risk of a cv event in an adult patient with elevated triglyceride levels and (1) established cv disease, or (2) diabetes mellitus and two or more additional risk factors for cv disease; Use of vascepa as an adjunct to statin therapy to reduce the risk of cardiovascular death in an adult patient with established cardiovascular disease; Use of vascepa as an adjunct to statin therapy to reduce the risk of unstable angina in an adult patient with established cardiovascular disease; Use of vascepa as an adjunct to statin therapy to reduce the risk of stroke in an adult patient with established cardiovascular disease; Use of vascepa as an adjunct to statin therapy to reduce the risk of a cardiovascular event in an adult patient with elevated triglyceride levels and at least one risk factor for cardiovascular disease; Use of vascepa as an adjunct to statin therapy to reduce the risk of a cardiovascular event (cardiovascular death, coronary revascularization and/or unstable angina) in an adult patient with elevated triglyceride levels; Use of vascepa as an adjunct to statin therapy to reduce the risk of a cv event (cv death, coronary revascularization, unstable angina, stroke and/or myocardial infarction) in an adult patient with elevated triglyceride levels and diabetes mellitus; Use of vascepa as an adjunct to statin therapy to reduce the risk of coronary revascularization and/or unstable angina in an adult patient with elevated triglyceride levels (tg >= 150 mg/dl to about 500 mg/dl); Use of vascepa as an adjunct to statin therapy to reduce the risk of a cardiovascular event (coronary revascularization, unstable angina, stroke and/or myocardial infarction) in an adult patient with elevated triglyceride levels; Use of vascepa as an adjunct to statin therapy to reduce the risk of cardiovascular death and/or coronary revascularization in an adult patient with elevated triglyceride levels (tg >= 150 mg/dl to about 500 mg/dl); Use of vascepa as an adjunct to statin therapy to reduce the risk of cardiovascular death, coronary revascularization, and unstable angina in an adult patient with elevated triglyceride levels (tg >= 150 mg/dl to about 500 mg/dl); Use of vascepa as an adjunct to statin therapy to reduce the risk of a cardiovascular event in a patient with prior percutaneous coronary intervention

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
1GM	CAPSULE;ORAL	Prescription
500MG	CAPSULE;ORAL	Prescription

111. Drug name - VELTASSA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9492476	VIFOR PHARMA	Potassium-binding agents for treating hypertension and hyperkalemia	Oct, 2033 (11 years from now)
US11123363	VIFOR PHARMA	Potassium-binding agents for treating hypertension and hyperkalemia	Oct, 2033 (11 years from now)
US9925212	VIFOR PHARMA	Potassium-binding agents for treating hypertension and hyperkalemia	Oct, 2033 (11 years from now)

Drugs and Companies using PATIROMER SORBITEX CALCIUM ingredient

Treatment: Treatment of hyperkalemia

Dosage: POWDER;ORAL

Strength	Dosage	Availability
EQ 8.4GM BASE/PACKET	POWDER;ORAL	Prescription
EQ 16.8GM BASE/PACKET	POWDER;ORAL	Prescription
EQ 25.2GM BASE/PACKET	POWDER;ORAL	Prescription

112. Drug name - VEMLIDY

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8754065 (Pediatric)	GILEAD SCIENCES INC	Tenofovir alafenamide hemifumarate	Feb, 2033 (10 years from now)
US9296769 (Pediatric)	GILEAD SCIENCES INC	Tenofovir alafenamide hemifumarate	Feb, 2033 (10 years from now)

Drugs and Companies using TENOFOVIR ALAFENAMIDE FUMARATE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 25MG BASE	TABLET;ORAL	Prescription

113. Drug name - VENCLEXTA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9539251	ABBVIE INC	Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor	Sep, 2033 (10 years from now)
US11110087	ABBVIE INC	Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor	Sep, 2033 (10 years from now)
US10993942	ABBVIE INC	Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor	Sep, 2033 (10 years from now)

Drugs and Companies using VENETOCLAX ingredient

Treatment: Treatment of adult patients with chronic lymphocytic leukemia (cll) or small lymphocytic leukemia (sll) in combination with a ga101 antibody such as obinutuzumab for one or more dosing periods, wherein the cll or sll is a cd20-expressing cancer; Treatment of acute myeloid leukemia (aml) by orally administering venetoclax with azacitidine or decitabine or low-dose cytarabine in adults 75 years or older or having certain comorbidities according to a dose ramp-up including a 100 mg per day dose; treatment of chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll) by orally administering venetoclax to an adult according to a dose ramp-up including a 100 mg per day dose; Treatment of chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll) by orally administering venetoclax to an adult according to a dose ramp-up that includes a dose of 50 mg per day for 1 week followed by 100 mg per day for 1 week

Dosage: TABLET;ORAL

Strength	Dosage	Availability
10MG	TABLET;ORAL	Prescription
50MG	TABLET;ORAL	Prescription
100MG	TABLET;ORAL	Prescription

114. Drug name - VIBERZI

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11160792	ALLERGAN HOLDINGS	Opioid receptor modulator dosage formulations	Mar, 2033 (10 years from now)
US10188632	ALLERGAN HOLDINGS	Opioid receptor modulator dosage formulations	Mar, 2033 (10 years from now)
US11007179	ALLERGAN HOLDINGS	Opioid receptor modulator dosage formulations	Mar, 2033 (10 years from now)
US11229627	ALLERGAN HOLDINGS	Opioid receptor modulator dosage formulations	Mar, 2033 (10 years from now)
US11090291	ALLERGAN HOLDINGS	Opioid receptor modulator dosage formulations	Mar, 2033 (10 years from now)
US9675587	ALLERGAN HOLDINGS	Opioid receptor modulator dosage formulations	Mar, 2033 (10 years from now)

Drugs and Companies using ELUXADOLINE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
75MG	TABLET;ORAL	Prescription
100MG	TABLET;ORAL	Prescription

115. Drug name - VICTOZA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9265893 (Pediatric)	NOVO NORDISK INC	Injection button	Mar, 2033 (10 years from now)

Drugs and Companies using LIRAGLUTIDE RECOMBINANT ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

Strength	Dosage	Availability
18MG/3ML (6MG/ML)	SOLUTION;SUBCUTANEOUS	Prescription

116. Drug name - VIEKIRA PAK (COPACKAGED)

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9629841	ABBVIE INC	Formulations of pyrimidinedione derivative compounds	Oct, 2033 (11 years from now)
US10201542	ABBVIE INC	Formulations of pyrimidinedione derivative compounds	Oct, 2033 (11 years from now)

Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR ingredient

Treatment: Treatment of hcv infection using dasabuvir

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 250MG BASE;12.5MG, 75MG, 50MG	TABLET;ORAL	Discontinued

117. Drug name - VIVLODEX

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9526734	ZYLA	Formulation of meloxicam	Mar, 2033 (10 years from now)

Drugs and Companies using MELOXICAM ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
5MG	CAPSULE;ORAL	Discontinued
10MG	CAPSULE;ORAL	Discontinued

118. Drug name - VOSEVI

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8940718 (Pediatric)	GILEAD SCIENCES INC	Antiviral compounds	May, 2033 (10 years from now)
US8921341 (Pediatric)	GILEAD SCIENCES INC	Antiviral compounds	May, 2033 (10 years from now)
US8575135 (Pediatric)	GILEAD SCIENCES INC	Antiviral compounds	May, 2033 (10 years from now)

Drugs and Companies using SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
400MG;100MG;100MG	TABLET;ORAL	Prescription

119. Drug name - VUMERITY

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10080733	BIOGEN INC	Prodrugs of fumarates and their use in treating various diseases	Sep, 2033 (10 years from now)
US8669281	BIOGEN INC	Prodrugs of fumarates and their use in treating various diseases	Sep, 2033 (10 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9090558	BIOGEN INC	Prodrugs of fumarates and their use in treating various diseases	Sep, 2033 (10 years from now)

Drugs and Companies using DIROXIMEL FUMARATE ingredient

Treatment: Method of treating multiple sclerosis

Dosage: CAPSULE, DELAYED RELEASE;ORAL

Strength	Dosage	Availability
231MG	CAPSULE, DELAYED RELEASE;ORAL	Prescription

120. Drug name - VYLEESI (AUTOINJECTOR)

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9700592	PALATIN TECHNOLOGIES	Uses of bremelanotide in therapy for female sexual dysfunction	Nov, 2033 (11 years from now)
US10286034	PALATIN TECHNOLOGIES	Uses of bremelanotide in therapy for female sexual dysfunction	Nov, 2033 (11 years from now)
US9352013	PALATIN TECHNOLOGIES	Uses of bremelanotide in therapy for female sexual dysfunction	Nov, 2033 (11 years from now)

Drugs and Companies using BREMELANOTIDE ACETATE ingredient

Treatment: Treatment of hypoactive sexual desire disorder (hsdd)

Dosage: SOLUTION;SUBCUTANEOUS

Strength	Dosage	Availability
EQ 1.75MG BASE/0.3ML (EQ 1.75MG BASE/0.3 ML)	SOLUTION;SUBCUTANEOUS	Prescription

121. Drug name - WEGOVY

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9764003	NOVO	Use of long-acting GLP-1 peptides	Jun, 2033 (10 years from now)

Drugs and Companies using SEMAGLUTIDE ingredient

Treatment: Method for weight management according to a dose escalation schedule

Dosage: SOLUTION;SUBCUTANEOUS

Strength	Dosage	Availability
0.25MG/0.5ML (0.25MG/0.5ML)	SOLUTION;SUBCUTANEOUS	Prescription
0.5MG/0.5ML (0.5MG/0.5ML)	SOLUTION;SUBCUTANEOUS	Prescription
1MG/0.5ML (1MG/0.5ML)	SOLUTION;SUBCUTANEOUS	Prescription
1.7MG/0.75ML (1.7MG/0.75ML)	SOLUTION;SUBCUTANEOUS	Prescription
2.4MG/0.75ML (2.4MG/0.75ML)	SOLUTION;SUBCUTANEOUS	Prescription

122. Drug name - XATMEP

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10231927	AZURITY	Methotrexate composition	Jan, 2033 (10 years from now)
US11116724	AZURITY	Methotrexate composition	Jan, 2033 (10 years from now)
US9855215	AZURITY	Methotrexate composition	Jan, 2033 (10 years from now)
US9259427	AZURITY	Methotrexate composition	Jan, 2033 (10 years from now)
US10610485	AZURITY	Methotrexate composition	Jan, 2033 (10 years from now)

Drugs and Companies using METHOTREXATE SODIUM ingredient

Treatment: A method for treating acute lymphoblastic leukemia; treatment of juvenile rheumatoid arthritis; Treatment of juvenile rheumatoid arthritis; a method for treating acute lymphoblastic leukemia

Dosage: SOLUTION;ORAL

Strength	Dosage	Availability
EQ 2.5MG BASE/ML	SOLUTION;ORAL	Prescription

123. Drug name - XHANCE

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11033696	OPTINOSE US INC	Nasal delivery devices	May, 2033 (10 years from now)
US10179216	OPTINOSE US INC	Nasal delivery devices	Jul, 2033 (10 years from now)
US10478574	OPTINOSE US INC	Nasal administration	Nov, 2033 (11 years from now)

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Treatment: Method of delivering fluticasone propionate to a nasal airway

Dosage: SPRAY, METERED;NASAL

Strength	Dosage	Availability
0.093MG	SPRAY, METERED;NASAL	Prescription

124. Drug name - XIIDRA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9085553	NOVARTIS	LFA-1 inhibitor and methods of preparation and polymorph thereof	Jul, 2033 (10 years from now)
US11058677	NOVARTIS	LFA-1 inhibitor formulations	Dec, 2033 (11 years from now)

Drugs and Companies using LIFITEGRAST ingredient

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

Strength	Dosage	Availability
5%	SOLUTION/DROPS;OPHTHALMIC	Prescription

125. Drug name - XIPERE

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9636332	BAUSCH AND LOMB INC	Methods and devices for the treatment of ocular diseases in human subjects	Nov, 2033 (11 years from now)

Drugs and Companies using TRIAMCINOLONE ACETONIDE ingredient

Treatment: Treatment of macular edema associated with uveitis

Dosage: SUSPENSION;INJECTION

Strength	Dosage	Availability
40MG/ML	SUSPENSION;INJECTION	Prescription

126. Drug name - XTORO

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9504691	MERLION PHARMS GMBH	Finafloxacin suspension compositions	Nov, 2033 (11 years from now)

Drugs and Companies using FINAFLOXACIN ingredient

Treatment: Treatment of acute otitis externa

Dosage: SUSPENSION/DROPS;OTIC

Strength	Dosage	Availability
0.3%	SUSPENSION/DROPS;OTIC	Discontinued

127. Drug name - XYOSTED (AUTOINJECTOR)

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10821072	ANTARES PHARMA INC	Needle assisted jet injection administration of testosterone compositions	Jun, 2033 (10 years from now)

Drugs and Companies using TESTOSTERONE ENANTHATE ingredient

Treatment: Method of administering testosterone enanthate subcutaneously

Dosage: SOLUTION;SUBCUTANEOUS

Strength	Dosage	Availability
50MG/0.5ML (50MG/0.5ML)	SOLUTION;SUBCUTANEOUS	Prescription
75MG/0.5ML (75MG/0.5ML)	SOLUTION;SUBCUTANEOUS	Prescription
100MG/0.5ML (100MG/0.5ML)	SOLUTION;SUBCUTANEOUS	Prescription

128. Drug name - XYREM

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10213400	JAZZ PHARMS	Method of administration of gamma hydroxybutyrate with monocarboxylate transporters	Mar, 2033 (10 years from now)
US9486426	JAZZ PHARMS	Method of administration of gamma hydroxybutyrate with monocarboxylate transporters	Mar, 2033 (10 years from now)
US9050302	JAZZ PHARMS	Method of administration of gamma hydroxybutyrate with monocarboxylate transporters	Mar, 2033 (10 years from now)
US8772306	JAZZ PHARMS	Method of administration of gamma hydroxybutyrate with monocarboxylate transporters	Mar, 2033 (10 years from now)
US10864181	JAZZ PHARMS	Method of administration of gamma hydroxybutyrate with monocarboxylate transporters	Mar, 2033 (10 years from now)
US8772306 (Pediatric)	JAZZ PHARMS	Method of administration of gamma hydroxybutyrate with monocarboxylate transporters	Sep, 2033 (10 years from now)
US9486426 (Pediatric)	JAZZ PHARMS	Method of administration of gamma hydroxybutyrate with monocarboxylate transporters	Sep, 2033 (10 years from now)
US9050302 (Pediatric)	JAZZ PHARMS	Method of administration of gamma hydroxybutyrate with monocarboxylate transporters	Sep, 2033 (10 years from now)

Drugs and Companies using SODIUM OXYBATE ingredient

Treatment: Method of reducing adverse effects in patients suffering from excessive daytime sleepiness and/or cataplexy in narcolepsy who are concomitantly administered sodium oxybate and divalproex sodium; Method of treating excessive daytime sleepiness and/or cataplexy in narcolepsy patients with sodium oxybate when divalproex sodium is concomitantly administered.

Dosage: SOLUTION;ORAL

Strength	Dosage	Availability
0.5GM/ML	SOLUTION;ORAL	Prescription

129. Drug name - XYWAV

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9132107	JAZZ	Gamma-hydroxybutyrate compositions and their use for the treatment of disorders	Jan, 2033 (10 years from now)
US10195168	JAZZ	Gamma-hydroxybutyrate compositions and their uses for the treatment of disorders	Jan, 2033 (10 years from now)
US8591922	JAZZ	Gamma-hydroxybutyrate compositions and their use for the treatment of disorders	Jan, 2033 (10 years from now)
US10675258	JAZZ	Method of using gamma-hydroxybutyrate compositions for the treatment of disorders	Jan, 2033 (10 years from now)
US8901173	JAZZ	Gamma-hydroxybutyrate compositions and their use for the treatment of disorders	Jan, 2033 (10 years from now)
US8772306	JAZZ	Method of administration of gamma hydroxybutyrate with monocarboxylate transporters	Mar, 2033 (10 years from now)
US9050302	JAZZ	Method of administration of gamma hydroxybutyrate with monocarboxylate transporters	Mar, 2033 (10 years from now)
US10213400	JAZZ	Method of administration of gamma hydroxybutyrate with monocarboxylate transporters	Mar, 2033 (10 years from now)
US9486426	JAZZ	Method of administration of gamma hydroxybutyrate with monocarboxylate transporters	Mar, 2033 (10 years from now)
US10864181	JAZZ	Method of administration of gamma hydroxybutyrate with monocarboxylate transporters	Mar, 2033 (10 years from now)

Drugs and Companies using CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE ingredient

Treatment: Treatment of cataplexy or excessive daytime sleepiness (eds) in patients 7 years of age and older with narcolepsy with a mixture of sodium, potassium, magnesium, and calcium salts of ghb; Method of treating patients with idiopathic hypersomnia with sodium oxybate when divalproex sodium is concomitantly administered; method of treating excessive daytime sleepiness and/or cataplexy in narcolepsy patients with sodium oxybate when divalproex sodium is concomitantly administered.; Method of treating excessive daytime sleepiness and/or cataplexy in narcolepsy patients with sodium oxybate when divalproex sodium is concomitantly administered.; Method of reducing adverse effects in patients suffering from excessive daytime sleepiness and/or cataplexy in narcolepsy who are concomitantly administered sodium oxybate and divalproex sodium; Method of treating excessive daytime sleepiness and/or cataplexy in narcolepsy patients with a salt of gamma-hydroxybutyrate when divalproex sodium is concomitantly administered

Dosage: SOLUTION;ORAL

Strength	Dosage	Availability
0.234GM/ML;0.096GM/ML;0.13GM/ML;0.04GM/ML	SOLUTION;ORAL	Prescription

130. Drug name - YOSPRALA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9987231	GENUS LIFESCIENCES	Compositions and methods for delivery of omeprazole plus acetylsalicylic acid	Jan, 2033 (10 years from now)
US9539214	GENUS LIFESCIENCES	Compositions and methods for delivery of omeprazole plus acetylsalicylic acid	Mar, 2033 (10 years from now)

Drugs and Companies using ASPIRIN; OMEPRAZOLE ingredient

Treatment: For secondary prevention of cardiovascular and cerebrovascular events in patients at risk of developing aspirin-associated gastric ulcers; Treatment or secondary prevention of cardiovascular disease, cardiovascular events, or cerebrovascular events and risk-reduction of aspirin-associated gastric ulcers

Dosage: TABLET, DELAYED RELEASE;ORAL

Strength	Dosage	Availability
81MG;40MG	TABLET, DELAYED RELEASE;ORAL	Discontinued
325MG;40MG	TABLET, DELAYED RELEASE;ORAL	Discontinued

131. Drug name - ZERVIATE

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9254286 (Pediatric)	EYEVANCE	Ophthalmic formulations of cetirizine and methods of use	Jan, 2033 (10 years from now)

Drugs and Companies using CETIRIZINE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

Strength	Dosage	Availability
EQ 0.24% BASE	SOLUTION/DROPS;OPHTHALMIC	Prescription

132. Drug name - ZOHYDRO ER

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10322120	RECRO GAINESVILLE	Treating pain in patients with hepatic impairment	Jul, 2033 (10 years from now)
US9326982	RECRO GAINESVILLE	Treating pain in patients with hepatic impairment	Jul, 2033 (10 years from now)
US9265760	RECRO GAINESVILLE	Treating pain in patients with hepatic impairment	Jul, 2033 (10 years from now)

Pharsight

Drug Patents Expiring in 2033

1. Drug name - ABILIFY MAINTENA KIT

2. Drug name - ABILIFY MYCITE KIT

3. Drug name - ACZONE

4. Drug name - AKLIEF

5. Drug name - ALKINDI SPRINKLE

6. Drug name - ANTARA (MICRONIZED)

7. Drug name - ARISTADA

8. Drug name - ARYMO ER

9. Drug name - AUSTEDO

10. Drug name - BAXDELA

11. Drug name - BELSOMRA

12. Drug name - BENDEKA

13. Drug name - BIKTARVY

14. Drug name - BONJESTA

15. Drug name - BRAFTOVI

16. Drug name - BYFAVO

17. Drug name - CABOMETYX

18. Drug name - CARNEXIV

19. Drug name - CEQUA

20. Drug name - CLOROTEKAL

21. Drug name - COMPLERA

22. Drug name - CONTRAVE

23. Drug name - CYTALUX

24. Drug name - DAPTOMYCIN

25. Drug name - DESCOVY

26. Drug name - DOCETAXEL

27. Drug name - EMPAVELI

28. Drug name - ENTRESTO

29. Drug name - EPANOVA

30. Drug name - EPCLUSA

31. Drug name - ERLEADA

32. Drug name - ESBRIET

33. Drug name - ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER

34. Drug name - EVOMELA

35. Drug name - EVRYSDI

36. Drug name - EYSUVIS

37. Drug name - FINTEPLA

38. Drug name - GENVOYA

39. Drug name - GIVLAARI

40. Drug name - HARVONI

41. Drug name - HETLIOZ

42. Drug name - HETLIOZ LQ

43. Drug name - ICLUSIG

44. Drug name - IDHIFA

45. Drug name - IMBRUVICA

46. Drug name - IMVEXXY

47. Drug name - INFUGEM

48. Drug name - INVELTYS

49. Drug name - IONSYS

50. Drug name - JENTADUETO XR

51. Drug name - KALYDECO

52. Drug name - KENGREAL

53. Drug name - KORLYM

54. Drug name - KYPROLIS

55. Drug name - LILETTA

56. Drug name - LINZESS

57. Drug name - LOKELMA

58. Drug name - LONHALA MAGNAIR KIT

59. Drug name - LORBRENA

60. Drug name - LUZU

61. Drug name - LYMPHOSEEK KIT

62. Drug name - MEKINIST

63. Drug name - MEKTOVI

64. Drug name - MITIGARE

65. Drug name - NAFTIN

66. Drug name - NOXAFIL

67. Drug name - NURTEC ODT

68. Drug name - OCALIVA

69. Drug name - ODEFSEY

70. Drug name - OMIDRIA

71. Drug name - ONIVYDE

72. Drug name - ONZETRA XSAIL

73. Drug name - ORFADIN

74. Drug name - OZEMPIC

75. Drug name - PEMAZYRE

76. Drug name - PHENYLEPHRINE HYDROCHLORIDE

77. Drug name - PHEXXI

78. Drug name - PICATO